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ABSTRACT
The transcatheter aortic valve replacement (TAVR) procedure has become a wellestablished procedure for high, intermediate-risk, and low-risk patients. However, there is
limited clinical data on the TAV's long-term durability, unlike SAV devices.
Computational simulations can be an alternative way to evaluate the TAV devices. This
dissertation aims to conduct structural and hemodynamic analyses on the TAV devices
under different conditions using computational simulation approaches.
Initially, the impact of the bicuspid aortic valve on the TAV devices was evaluated.
The result indicated that the CoreValve-like supra-annular self-expandable device was
likely to have increased stress and strain on the leaflet when it was elliptically deployed.
The impact on the intra-annular balloon-expandable design was minor in the clinic.
Subsequently, the effect of regional under-expansion on the supra-annular selfexpandable device was studied. The simulations showed that the reduced leaflet angle
could impair leaflet motion and increase stress. The small-angle leaflet was likely to fail
over time. The hemodynamic analysis was conducted on both super-annular and intraannular designs in pulse duplicator models. The result proves that the thrombosis is likely
to initiate at the fixed edge of the intra-annular design and lower belly region of the
supra-annular design. Most of the blood within the neo-sinus region in the supra-annular
design could be washed out within one cardiac cycle. However, the blood near the fixed
could accumulate and increase thrombosis risk.
ii

Furthermore, the BASILICA procedure was investigated with an intra-annular design
in a patient-specific geometry. This procedure could considerably reduce the blood stasis
on the leaflets. The reduction can be as high as13.2 % on the left coronary leaflet. The
presented works showed that the design improvement should be focused on the region at
the lower belly region in the supra-annular design and the fixed edges in the fixed edge of
the intra-annular design to improve the long-term durability of the TAV devices. The
BASILICA could be an alternative way for physicians to reduce the thrombosis risk.
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Chapter One: Introduction
1.1

Heart Structure and Function
The heart is one of the major organs in the body. It is responsible for pumping the

blood through the body to carry oxygen and other nutrition to support its normal
functions. The heart consists of the left side and the right side. Each side has two
chambers, atria and ventricles, and two valves regulate the blood flow direction on each
side. The function of the left heart is to transfer blood from the system circulation to the
pulmonary circulation. The right side of the heart can regulate the oxygenated blood flow
from pulmonary circulation to system circulation. The left side of the heart has a thicker
muscle wall than the right side because the left side of the heart will experience a highpressure gradient, which is usually as high as 120 mmHg in an average person.
During normal cardiac cycles, oxygen is transferred from oxygenated blood to the
other part of the body. The cardiac cycle can be separated into two phases, diastole and
systole. In late diastole, deoxygenated blood enters the right atrium from the inferior and
superior vena cava. Meanwhile, the oxygenated blood fills the left atrium. Following the
filling of the atria, the mitral and tricuspid valve opens. The blood then flows into the
ventricles. More blood is pushed into the ventricle during atrial contraction. The atrial
valves (mitral and tricuspid valves) are closed when the ventricles are filled with blood.
However, their pressure is not high enough to open the aortic valve and pulmonary valve.
Subsequently, the ventricular pressure builds up as the ventricle contracts and the
1

semilunar valves (aortic and pulmonary) valve open. As a result, the deoxygenated blood
is ejected into the pulmonary circulation. In contrast, the oxygenated blood is discharged
into the systematic circulation. After the blood flow through the circulations, the next
cardiac cycle initiates by filling the atria chambers1.

Figure 1.1 Heart structure and flow direction: The green arrow indicates the flow
direction on the left side of the heart, and the red arrows indicate the flow direction on the
right side of the heart.
1.1.1

Aortic Valve Structure and Function

The aortic valve leaflet has a semilunar shape. It locates at the aortic annulus. It
regulates the blood flow from the left ventricle (LV) to the aorta and prevents the blood
flow back to the LV during diastole under high pressure. The anatomical structure of the
aortic valve is presented in Figure 1.2. Two leaflets face the coronary arteries, the left,
2

and right coronary arteries. The other leaflet is not facing any of the coronary. There is a
sinus region around the leaflet so that either coronary artery cannot be blocked when the
valve is opened.

Figure 1.2 Structure of the aortic valve. (A: three-dimensional arrangement of the
valve. B: the anatomy of the aortic valve)2
1.2

Cardiovascular Diseases
The heart holds a critical function in the body. However, risk factors like aging,

overweight, and an unhealthy diet can potentially lead to the malfunction of the heart.
Heart and blood vessel disorders can be categorized as cardiovascular diseases (CVDs).
According to the World Health Organization (WHO), they are the top cause of death
globally. 17.9 million deaths are due to this type of disease annually, consisting of 32%
of the total death in the world3.
3

1.3

Valvular Heart Diseases
As the center of the pumping system in the body, heart valves are one of the

prominent locations that can be malfunctioned. It consists of 10-20% of the total cardiac
surgical procedures in the US4. Nearly 25,000 deaths are caused by this type of disease in
the US alone each year5.
It may happen on any of the four valves in the heart. The cause of Valvular Heart
Diseases (VHDs) can be separated into three major categories. Genetic defects usually
cause congenital heart valve diseases. Rheumatic disease is the most common VHD
cause. It can leave scars on the leaflets, which impair the function of the valves. The third
type of leading cause is endocarditis. The server infection triggers this type of cause in
the blood. The infections can lead to damage to the leaflets6.
Valve stenosis and regurgitation are two common problems with malfunctioned
valves. Both of them can impair the function of the heart. One can get both stenosis and
regurgitation on one or multiple valves simultaneously. When a patient has stenosis or
regurgitation, the heart cannot pump enough blood through the body. The patient may
experience chest pain, irregular heartbeats, fatigue, and other symptoms. In the worst
case, the patient can have a heart attack or even heart failure7.
1.4

Valvular Stenosis
Valvular stenosis narrows the opening of the valve. The flow out of the valve is

restricted. The age-related calcifications formation commonly causes it on the leaflets8.
Congenital defects, such as the bicuspid aortic valve and rheumatic disease, can also
cause this problem. Among those causes, calcification is one of the most common
4

triggers of Aortic Stenosis (AS). 2-4% of adults over age 65 are diagnosed with
calcification-related aortic stenosis9.
The aortic valve has a higher chance of experiencing stenosis when compared with
the other valves. Aortic stenosis (AS) results from progressive aortic valve leaflet
thicking and stiffing. It is initiated with damage to the endothelial layer. The lipid and
inflammatory cells were able to infiltrate into the damaged site and further lead to the
formation of fibrous tissue in the valve10.
Early-stage AS is hard to diagnose because it usually has a long latent peroid11.
During the progression of the AS, the LV is likely to have hypertrophic changes because
of the outflow obstruction. However, the increased systolic function from the LV can also
lead to increased LV filling resistance, which will cause dysfunctional diastole12. As the
AS develops, the patient may experience heart failure. Aortic valve replacement is
recommended to treat patients with severe AS conditions11.

5

Reproduced with permission from (scientific reference citation), Copyright
Massachusetts Medical Society.
Figure 1.3 Calcific aortic stenosis mechanisms13
1.5

Thrombosis
Thrombosis is the accumulation of thrombus, known as the formation of blood clots.

When it happens at the leaflet, it could impair the leaflet kinematics. It can lead to stroke
and heart attack. In the worst case, the patient may die from this.
1.5.1

Thrombosis Formation Cascade

The blood clotting system as a protection system resides in mammalian bodies. It is
one essential mechanism to prevent blood loss following injury. It consists of a series of
enzyme activation events in the body. Those events led to fibrin polymerization and
platelet activations. Finally, the blood clots are formed14.
Two pathways in the body can trigger blood clotting: the tissue factor pathway and
the contact pathway. Both of the pathways contribute to thrombosis. When one of the
6

pathways is triggered and actions at the unwanted location, the thrombosis is initiated,
termed pathologic thrombosis.

Figure 1.4 Physiological blood clotting cascade15
The tissue factor (extrinsic) pathway is triggered following factor VII (FVII) binds
with cell membrane-bounded receptor tissue factor (TF). The FVII is automatically
activated and becomes FVIIa. The formed TF: VIIa complex can stimulate the factor X
(FX) to its activated form FXa. The contact (intrinsic) pathway is initiated with the
activation of factor IX (FIX). Initially, factor XI (FXI) is expressed on the activated
platelets. Subsequently, the FXI activates FIX to FIXa. When FIXa is exposed to factor
VIII (FVIII), they can convert FX to FXa. Both of the pathways are converged to the FX.
The FXa can combine with factor V and form prothrombinase in the final common
pathway, transforming prothrombin into thrombin. The burst production of thrombin
stimulates the formation of fibrin from fibrinogen. Finally, the clot is formed14,15.
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1.5.2

Virchow’s Triad

Virchow’s Triad is named after German physician Rudolf Virchow. Although
Virchow does not propose Virchow’s Triad, his extensive work on venous thrombosis
and pulmonary embolism provided a large amount of experimental evidence about the
cause of thrombosis. Virchow’s Triad proposed that blood flow stasis, endothelial
damage, and hypercoagulability are related to the formation of thrombosis. It provided
clinicians understanding of the factors that contribute to thrombosis formation16,17.

Figure 1.5 The Virchow’s Triad
In addition to the thrombosis formation pathology described in 1.5.1, blood flow
stasis is another primary cause of thrombosis. Lowe concluded that the high shear stress
could activate the platelets, mainly located at the wall, and promote the washout of the
thrombin 18. Stasis is required to allow the thrombin to accumulate and form thrombosis.
Neo-sinus is one of the few locations that fit all of the conditions. It has a low flow
velocity, while the shear stress at the location is relatively high due to the movement of
the leaflets19.
8

1.6

Aortic Valve Replacement (AVR)
AVR is the only practical option for patients with severe AS to restore normal cardiac

function11. American Heart Association (AHA) and the American College of Cardiology
(ACC) have provided guidelines for treating patients with aortic valve disease20.

Figure 1.6 Indications for Aortic Valve Replacement13
9

Initially, the physicians assess the risk of the patient based on the severity of the AS
based on several indicators. The commonly used indexes are the maximum transvalvular
velocity, mean transaortic pressure gradient, and aortic valve area. When the
transvalvular velocity exceeds four times the normal velocity, the patients may need their
aortic valve replaced. However, some symptomatic patients may have valve obstruction
with a low velocity and pressure gradient. The aortic- valve area becomes a critical index
to identify the severity. If the patient needs to receive the valve replacement procedure,
physicians may need to evaluate the patient’s conditions to assert which approach to use.
There are two major approaches: surgical valve replacement and transcatheter aortic
valve replacement13.
1.6.1

Surgical Aortic Valve Replacement (SAVR)

SAVR used to be the only approach to replace the aortic valve with severe stenosis
until recent decades. It requires open surgery for the surgeon to access the heart and
replace the malfunctioned valve. It is commonly used for low or intermediate-risk
patients. Those patients are expected to have longer life expectations and a high survival
rate after surgery. There are two major types of surgical valves. They are mechanical
valves and bioprosthesis valves21.
1.6.1.1

Mechanical Valve

The mechanical valve has been used for 70 years and showed a remarkable low
mortality rate and lifetime complication rate in the patient22. This type of valve can stay
in the patient without mechanical failure for 30 years. However, the patients need to take
lifelong anticoagulation to prevent thrombosis due to the valve material and kinematics.
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This type of valve was firstly introduced in 1952. Currently, there are six mechanical
valves commercially available22. They are mainly categorized into three types, bileaflet
valve, monoleaflet valve, and caged ball valve. The geometries are shown in Figure 1.7.

Figure 1.7 Common types of mechanical valves23
1.6.1.2

Surgical Biological Valve

The surgical biological valves were first introduced based on the idea of reducing
thromboembolic events24. They used biological materials to create their leaflets to reduce
the immune rejection events in the patient. Although the biological material can help
reduce the thromboembolic events and is superior in hemodynamics when compared with
the mechanical valve, this type of surgical valve has a shorter life in the patient’s body
due to material fatigue.
Ideally, the allografts or the autografts could minimize the rejection from the body
and avoid taking anti-coregulation. However, the cadaveric aortic valve is difficult to
obtain, and not all patients can provide autograft. Therefore, the xenografts, primarily
ovine, bovine, or porcine, were considered when designing the valve device25. Based on
the stent, they can be separated into stented and stentless valves. The common surgical
biological valves are presented in Figure 1.8.
11

Figure 1.8 Common surgical biological valves25
1.6.2

Transcatheter Aortic Valve Replacement (TAVR)

TAVR is a minimum invasive approach to replace the dysfunctioned valve. It is ideal
for high-risk patients since it deals less damage than the surgical approach to the body
and increases the subclinical survival rate. It has become a standardized procedure for
high and intermediate-risk patients26-32. The physicians explored the opportunity to use
this procedure in low-risk patient27,32,33. The promising short-term results have granted
TAVR FDA approval for its use in low-risk patients.
TAVR is initially used for patients with high risk. Regarding its excellent result,
people are exploring the potential to use this procedure in more patients. Studies have
shown that the patients who received TAVR have a similar outcome to the intermediaterisk patients treated with the surgical approach28. Transfemoral, transapical,
subclavian/axillary, and direct aortic accesses are four primary access methods
commonly used during TAVR. Transfemoral access is the most common approach
consisting of 80% of the procedures34.
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In the transfemoral access procedure, the access site is located above the femoral
bifurcation. Initially, a guidewire is inserted in the femoral artery retrogradely with the
help of fluoroscopic guidance. Subsequently, the femoral artery is dilated with a vascular
inducer sheath to facilitate a preclosure suture device, providing vascular access entry for
the TAV devices. After placing the preclosure suture device, the inducer sheath is
reinserted into the vessel to reduce the backside bleeding. Then the standard guidewire is
replaced with a long stiff wire through a pigtail catheter to the descending aorta to
provide enough support for the placement of the valve delivery sheath. Anticoagulation is
used following this procedure to prevent blood clots. The prepared TAV can be delivered
through the delivery sheath to the dysfunctioned aortic valve location.

Figure 1.9 Transfemoral access approach. (a. Crimped balloon-expandable valve on a
balloon at the tip of the delivery catheter. b. Expanded valve device at the aortic position.
c. The delivered valve)35
The transapical access procedure creates an anterolateral mini-thoracotomy incision
at the submammary fold, located between the fifth or sixth intercostal space. The
guidewire reaches the degenerated aortic valve from a myocardial puncture created at the
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ventricular apex with the facilitation of a right Judkins catheter. Following the placement
of the guidewire, a long stiff wire is placed through the same catheter to provide support
for the delivery sheath. In this procedure, the delivery sheath is placed through the
myocardium and placed below the dysfunctioned aortic valve. Subsequently, the TAV is
delivered to the diseased location via the delivery sheath.

Figure 1.10 Transapical access approach. (a. Crimped balloon-expandable valve on a
balloon at the tip of the delivery catheter via left ventricular apex. b. The expanded valve
at the diseased location)35
Subclavian/axillary access is used when the patient’s peripheral artery condition does
not allow the other implantation method. It can provide more implantation angles during
the procedure. The access site is located at the subclavian artery. Like the transfemoral
approach, the delivery sheath is placed through the ascending aorta34. However, the
puncture on the subclavian artery during this procedure is likely to lead to life-threatening
complications. Therefore, it became less popular and replaced the direct aortic
approach35.
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Direct aortic access approach, the insertion is opened at the mid-clavicular region or
the right parasternal region. The delivery sheath is placed via the puncture on the
ascending aorta. Like the transfemoral access method, the bioprosthesis is deployed to the
aortic position through the delivery sheath34.

Figure 1.11 Direct aortic approach. (a. Stiff wire through the arterial puncture across
the aortic valve. b. Large-born arterial access sheath with crimped TAV delivery catheter.
c. Self-expandable valve deploying at the aortic position.)35
The balloon pre-dilatation is an optional procedure before the implantation of the
TAV device. During this procedure, a small size balloon is delivered to the valve location
and expanded during a rapid heartbeat. It is helpful regarding the separation of the fused
commissures, fracture of the intra-leaflet calcified nodules, and improvement of the
rigidly calcified aortic root compliance34.

Figure 1.12 Common transcatheter heart valves25
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According to the implantation location, the device can be divided into two major
types based on the delivery method: balloon expanded valve and self-expandable valve.
They can be categorized into intra-annular design and supra-annular design.
1.6.2.1

Balloon Expandable Valve

Balloon expandable requires the balloon to expand the crimped valve to the designed
geometry. The valve devices were crimped on a balloon during the preparation phase.
During the procedure, it is delivered to the diseased location. Subsequently, the valve
device is expanded to the designed shape by the radial direction force generated by the
balloon expansion. Edwards SAPIEN series valves are the most commonly used balloonexpandable bioprostheses. The different generations of the valve devices are illustrated in
Figure 1.14.
The first balloon-expandable valve used in humans, the Cribier-Edwards valve, was
designed by mounting three bovine pericardial leaflets on a stainless steel stent36. The
Edwards SAPIEN valve is the first iteration of the device improvement. A polyethylene
terephthalate (PET) fabric skirt is introduced in this device in addition to the tri-leaflet
bovine pericardium and the stainless steel. The stent design is improved in the Edwards
SAPIEN XT valve. The material of the stent is changed to cobalt-chromium for better
biocompatibility. A reduced profile stent is applied in this design. It has fewer rows and
columns. In addition, the number of verticle struts is also reduced between
commissures37.
The Edwards SAPIEN 3 valve device is the most widely used balloon-expandable
device. There is a major change in the stent design to reduce the profile further. This type
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of device can fit into 14 Fr and 16 Fr expandable introducer sheaths for ≤26mm diameter
and 29 mm diameter devices, respectively38. This design has an additional outer PET
skirt layer to reduce paravalvular leakage37. The most recent generation is SAPIEN 3
Ultra. It continued the improvement in the reduction of paravalvular leakage, which
reflects in the change of the outer PET skirt. The SAPIEN 3 Ultra has a 40% increased
height and 50% additional surface contact area with the native valve anatomy39.

Figure 1.13 The delivery of Edwards SAPIEN XT device. (a. Edwards SAPIEN XT
device; b. Crimped Edwards XT valve on the delivery system; c. Fully expanded
Edwards XT valve on the delivery system)35

Figure 1.14 Edwards SAPIEN valve series40
1.6.2.2

Self-Expandable Valve

Another common type of TAV is the self-expandable valve. The self-expandable
valve device does not require a balloon to facilitate the valve deployment. During the
TAVR procedure, the crimped valve device can recover to its designed shape once
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released. This recovery is supported by the shape memory behavior of the nitinol alloy
stent. The nitinol alloy exhibits similar mechanical behavior to natural materials such as
hair and bone. Those types of material can be elastically deformed up to 10% strain in a
non-linear fashion41. They are categorized as superelastic material.
Medtronic CoreValve series (Medtronic, Minneapolis, MN) valves are the most
commonly used commercially available device. The three different iterations of the
CoreValve series devices, CoreValve, CoreValve Evolut R, and CoreValve Evolut Pro,
are presented in Figure 1.15. The overall profile of the prosthesis has an hourglass shape
to enhance the fixation and sealant of the valve device at the diseased location. The
CoreValve is the first generation self-expandable valve device available in the market.
The skirt and the leaflet are made with one piece of porcine pericardium material. It has
shown a superior result compared with the SAVR in high-risk patients42-44. This device
system is relatively large and requires an 18 Fr to 24 Fr catheter to deliver the device to
the diseased location45.
The second-generation self-expandable valve device, CoreValve Evolut R, was
carried out to reduce the valve device profile and the paravalvular leakage. It has reduced
overall height with an identical skirt height. This design improvement enables the
device’s in-catheter profile to be reduced to 14 Fr to 16 Fr. It can help the device be
delivered through a smaller diameter vessel. The material of the leaflet and skirt is still
the porcine pericardium. Additionally, the retrievable feature is added to the delivery
system allowing the physician to gain the ability to reposition the valve to have an
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optimal result45. Clinical studies have found that the CoreValve Evolut R system has
significantly reduced paravalvular leakage compared with the CoreValve system46-48.
The CoreValve Evolut Pro system is developed based on the Evolut R series. The
major change in this design is the additional external pericardial wrap around the skirt. It
introduced an additional contact area and tissue volume between the prosthesis and the
native anatomy. Together with the radial force provided by the shape memory stent, this
feature improves the sealing following TAVR45,49. However, the additional layer also
increased the profile of the valve device. The minimum accessible vessel for the crimped
valve device is 5.5 mm. Another limitation is that the CoreValve Evolut Pro system is
only available in sizes larger than 30 mm. The CoreValve Evolut Pro Plus is the latest
iteration of the series to resolve this issue. It is available in a broader range of sizes,
including 23, 26, 29, and 34 mm. The smaller devices, 23 to 29 mm, can access a 5 mm
diameter vessel, while the 34 mm device can pass through a 6 mm vessel50.

Figure 1.15 Medtronic CoreValve series45
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1.6.2.3

Problems Related to TAVR

Paravalvular leakage51,52, vascular and bleeding complications, stroke, acute kidney
injury, and condition abnormalities are the common problems following TAVR53. The
design improvements of both balloon-expandable and self-expandable valves are targeted
to alleviate those problems. The paravalvular leakage is mainly caused by insufficient
contact between the prosthesis and the local geometry in the patient. Blood can leak
through the gap and cause regurgitation during the normal cardiac cycle. The
regurgitation can negatively post-procedural outcome of TAVR and lead to dramatically
increased morbidity and mortality52.
1.6.3

Cause of TAV Failure

The materials of the biological heart valves are usually made with heterograft tissues,
such as porcine aortic valves and bovine and porcine pericardium54,55. The tissue
materials are commonly treated with glutaraldehyde because the glutaraldehyde treatment
can reduce the immune response and stabilize the tissue ultrastructure via crosslinking
free lysine residues56,57. However, this treatment can not completely remove the
antigenicity on the material. The macrophages, T cells, and eosinophils can still respond
to the xenografts by infiltration through the structure56.
Since the surgical bioprostheses and transcatheter bioprostheses are made with
biological material, commonly pericardium, the common issues on the TAV are similar
to that on the SAV. Mylotte et al. systematically reviewed 2400 clinical research papers
and identified 87 TAV failure cases from 70 publications to evaluate the common failure
mode following the TAVR58. Calcification, noncalcific structural deterioration, and
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leaflet thrombosis are three distinct mechanical related mechanisms of the early failure
mode of TAV59-61.
1.6.3.1

Calcification

The calcification is a complex procedure involving several different residents,
circulation, and bone marrow-derived cells62,63. It is the result of calcium accumulating in
the collagen/elastin matrix of the biological material. In the normal native valve,
endothelial cells and interstitial cells function as a barrier to protect the valve. The
calcification procedure is usually associated with the dysfunction of endothelial cells and
the infiltration of inflammatory and immune cells. Those events could result in the
leaflet's remodeling, fibrosis, and calcification formation62. However, those cells are
missing in the bioprosthetic material. Additionally, the decellularization procedure could
result in residuals on the material, contributing to the initiation of the calcification. For
example, membrane-bounded phospholipids are found to promote calcification
nucleation64. Residuals introduced during the deceleration procedure, like aldehydes on
the structure, could lead to the calcification formation65.
1.6.3.2

Noncalcific Structural Deterioration

Noncalcified structural deterioration fatigue is one of the primary failure modes of the
bioprosthetic heart valve. Both biological and mechanical processes contribute to the
deterioration of the biological material leaflet. The mechanically induced structural
damage on the leaflet, such as leaflet tears and perforations, can initiate the pathways in
the chemically treated soft tissue material66. Sacks et al. 67 found that the collagen fiber
structural change in the biological heart valve is independent of the calcification.
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The majority of the noncalcific structural deteriorations are linked to cyclic
fatigue68,69. Vyavahare et al.70 observed the progressive loss of collagen helicity and
glycosaminoglycans in the porcine aortic valve in an in vitro fatigue study. The cyclic
load can induce elastin damage, which elongates the tissue, reduces extensibility, and
increases stiffness. The cyclic load-induced damage over time can ultimately lead to
material fatigue66,71.
The mechanical testing of soft tissue fatigue is time-consuming and hard72. Therefore,
Martin et al.73 developed the fatigue model for the TAV and SAV. The result showed a
high correlation with the fatigue location in the localized high stress and strain region.
Thus, studying the stress and strain on the leaflets of the bioprostheses is critical for us to
understand fatigue-related biological heart valve device failure.
1.6.3.3

Leaflet Thrombosis

The bioprosthetic valves are less likely to develop thrombosis when compared with
the mechanical valve. Clinical reports indicate that the likelihood of thrombosis following
TAVR is relatively rare and commonly can be resolved by taking anticorrelation74-76.
However, the risk of thrombosis in TAV is higher than that in SAV77. Furthermore,
although it is a rare event, it needs to be addressed to prevent severe consequences, such
as stroke and heart failure.
The thrombosis formation mechanism on the bioprosthesis is similar to that on the
native valve. Some potential risk factors in TAV can lead to increased thrombosis
formation risk. Firstly, the metallic frame could provide a nidus for the initiation of
thrombosis. The incomplete expansion of the TAV can create the folded sit on the leaflet
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for thrombosis formation. Additionally, the inaccurate TAV positioning can postpone the
endothelization on the leaflet. The neo-sinus region between the native and newly
implanted valves creates a flow stagnation region. Finally, the blood is more likely to
have increased stasis time in that region and form thrombosis58.
1.6.3.4

Related Problems

The structural change of the bioprostheses, such as calcification and thrombosis, can
directly lead to insufficient valve opening or stenosis. The structural change, in turn,
causes the altered fluid dynamic behavior of the blood near the valve.
4-dimensional computed tomography (CT) scan is the gold standard for diagnosing
subclinical leaflet thrombosis following the TAVR. One of the major characteristic
findings is hypoattenuating opacity located at the leaflet base, defined as hypoattenuating
leaflet thickening (HALT). HALT has been observed following TAVR with both
balloon-expandable and self-expandable valve device78,79. However, HALT happens
more frequently on the balloon-expandable valve device80. HALT can lead to the
reduction of leaflet mobility. Hypoattenuating affected motion (HAM) is presented in the
patient if both HALT and reduced leaflet mobility are observed under CT
simultaneously81,82. Most of them can be resolved by anticoagulation therapy, whereas
antiplatelet therapy does not show a superior outcome. Not all patients are suitable for the
anticoagulation treatment since anticoagulation is associated with an increased risk of
bleeding79,83.
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Figure 1.16 Examples of HALT in TAV84
Paravalvular leakage, also known as paravalvular regurgitation, is one of the major
issues after TAVR. The increased paravalvular leakage can potentially lead to a higher
risk of morbidity and mortality. It is usually caused by the mismatch of the device size
and the annulus size52. The new generation transcatheter aortic valve devices, such as
CoreValve Evlut R, and SAPIEN 3 Ultra, focused on reducing paravalvular leakage by
modifying the skirt design.
Since the bioprostheses are made with biological material and may face the same
issues that happen on the native valve in the middle to long term after the implantation,
stenosis is one of them. The progression of the stenosis may lead to insufficient leaflet
opening and closing, leading to transvalvular regurgitation.
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1.6.4

Study Significance

While the TAVR has become more and more popular in treating patients with
dysfunctional valves, studies are exploring the possibility of using this technique on lowrisk patients. The durability of the valve device has become one of the major challenges
that we need to address.
The in-vivo environment is not ideal, and the patient-specific geometry has different
characterizations. Therefore, the valve device can not be deployed as the labeled shape in
most patients due to the complex local geometry. For example, congenital heart valve
disease, bicuspid aortic valve, geometry has narrowed orifice. The valve deployed in
those patients usually results in an elliptical shape. The TAV can be deployed unevenly
in the highly calcified local annulus geometry. The stress and strain distribution on the
leaflet might be altered in those configurations and further increase the risk of the noncalcific deterioration of the leaflet. It could impair the long-term durability of the valve
device in the patient.
The valve-in-valve procedure has become a standard procedure for the patient who
has received the valve replacement procedure, either SAVR or TAVR, and the device is
dysfunctioned. However, clinical research has shown an increased thrombosis risk
following the valve-in-valve and TAV procedure. The implantation of the TAV could
induce a neo-sinus region since the procedure does not remove the old leaflet. The
analysis of the thrombosis formation risk in the neo-sinus region could shed light on the
valve's mechanism in valve configuration.
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There are two major sections in this dissertation. Initially, structural analysis of the
valve devices in different configurations was investigated in section one. In chapter two,
the scenario in bicuspid aortic valve patients was considered by analyzing the impact of
ellipticity and underexpansion on the valve device. Chapter three discussed the regional
underexpansion impact when one leaflet was less than 90 degrees.
Subsequently, the second section asserted thrombosis risks by analyzing the blood
stasis time using a fluid-solid interaction simulation. Three projects were conducted to
analyze the blood stasis time at the neo-sinus region following the intra-annular and
supra-annular TAV design implantation.
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Chapter Two: Transcatheter Aortic Valve in Bicuspid Aortic Valve Patient
2.1

Overview
The bicuspid aortic valve is a common congenital defect associated with a high risk

of aortic valve dysfunction. The dysfunctioned bicuspid aortic valve has a narrow
opening. Thus the TAV is usually deployed in an elliptical shape. This study aims at
investigating the impact of the elliptical shape on the TAV.
2.2

Background
The bicuspid aortic valve (BAV) is a common congenital cardiac anomaly with a

high prevalence, 0.5%–2% of the world population85. 20%-50% of the BAV patients
need to receive valve replacement procedures in their lifespan86-88.
The prevalence of the BAV is related to several factors, such as gender and age. The
male is more likely to have BAV than the female89,90. The risk of complications, such as
AS, has a high prevalence in the younger BAV patient. Clinical studies have found that
the progression of AS is faster in patients with BAV. Sclerosis initiates after 20 years old,
and calcification is found predominately in patients older than 40 years91,92. The
prevalence also can vary in different regions. Although the echocardiographic database
indicates the incidence of BAV in China is similar to the western world, nearly half of the
patients who received TAVR had a BAV91,93.
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Figure 2.1 Schematic presentations and echocardiographic images of three different
BAV types. Red bolded lines represent the merged raphes. R: right coronary leaflet; L:
left coronary leaflet; N: non-coronary leaflet94.
There are three major types of BAV. As shown in Figure 2.1, type 0 BAV does not
have raphe. It opens either horizontally or vertically. Type 1 BAV has one raphe, which
merges two leaflets’ free edges. Finally, the type 2 BAV has two raphes. Since the two
raphes connect three leaflets, it is also known as the unicuspid aortic valve.
The BAV was considered a contraindication for TAVR due to the risk introduced by
the eccentric annulus, asymmetrically distributed calcification, and unequal-sized
leaflets95. In addition to the fact that BAV stenosis has more incidence in the younger
patient. Concerns have been raised about the durability of the TAV device in those lowrisk patients. Although the TAVR in low-risk patients has shown a promising result27, the
patients with BAV stenosis were excluded in the pivotal randomized clinical trials26,42.
The feasibility of the TAVR in BAV patients has been evaluated with the normal
tricuspid aortic valve patient96-98. The short-term follow-up studies have shown a
favorable outcome99,100. Given the high success rate of the new generation self-
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expandable and balloon-expandable valves, the TAVR could be an ideal approach for
low-risk BAV patients. However, the long-term durability is still unknown.
Before the TAVR is entirely accepted for low-risk patients, the durability of the
transcatheter aortic valve devices needs to be proven to be comparable with the surgical
bioprosthetic valve device. The complex local geometry in BAV patients, such as the
asymmetrical annulus and unevenly distributed calcification, prevents the TAV devices
from being deployed as designed circular shapes. This impact can vary in different valve
devices and usually exhibits a specific stent distortion behavior following TAVR.
Edwards SAPIEN 3 valve (Edwards Lifesciences, Irvine, CA) is the most commonly
used TAV device in bicuspid valves due to its balloon-expandable feature. Although
research has found no difference between BAV and tricuspid aortic valve in annulus
eccentricity under contrast-enhanced CT, the TAV device in the BAV patients presents a
higher stent eccentricity at all cross-sectional levels, including inflow-level, mid-level,
and outflow-level101. The ellipticity index and expansion ratio are commonly used to
describe the ellipticity and underexpansion of the deployed device. The ellipticity is
defined as long axis length/ short axis length. The expansion ratio is calculated by TAV
external area/ device labeled area ×100. The average ellipticity index of the SAPIEN 3
valve device at the annulus level is 1.06 and 1.03 (p<0.001) in BAV and tricuspid aortic
valve patients, respectively. The SAPIEN 3 is usually deployed with an hourglass shape
due to the constraints. This expansion ratio is reduced from 98.3 ± 7.7% to 93.9 ± 6.7%
(p<0.001) at the middle level of the SAPIEN 3 valve device in BAV patients.
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The self-expandable valve device Medtronic CoreValve (Medtronic, Minneapolis,
MN) is also used in BAV patients. However, this device is highly impacted by the local
confinement99,102. Oversizing is another term used to evaluate the expansion of the
device. It is defined as ((device area – annulus area)/annulus area) × 100. Yoon et al.99
have observed that the area oversizing of the CoreValve device is 33.1 ± 18.2 %, and it is
much higher than that in the SAPIEN 3 valve device, which is 12.9 ± 1.8%. Schultz et
al.103 found that the eccentricity decreases from the inflow to the outflow. The average
ellipticities were found to be 1.25 at inflow, 1.18 at the nadir of leaflets, 1.12 at
coaptation level, and 1.05 at commissure level. The expansion ratio has a similar trend to
the ellipticity.
This study aims to determine the synergistic effect of elliptical and incomplete stent
deployment on the TAV using experimental testing and finite element analysis. The
stress and strain distributions have a high correlation with fatigue73. The stress and strain
distribution analysis could provide insight into the TAV devices' long-term durability. In
some of the previous structural analyses of the transcatheter aortic valve device, the
balloon-expandable SAPIEN XT valve was evaluated with a high ellipticity index,
1.4104,105. However, clinical studies do not observe this high ellipticity in BAV patients
who receive a balloon-expandable valve device. The high ellipticity is observed on the
self-expandable CoreValve device in both BAV and tricuspid aortic valve patients.
However, the supra-annular designed CoreValve may have a different response to the
high ellipticity and low expansion ratio when compared with the intra-annular design.
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This study implemented the ellipticity and expansion ratio based on the clinical studies
aiming at the configurations that frequently happen in reality.
2.3

Method
2.3.1

Experimental Setup

The cases analyzed in this study are based on clinical studies99,101,103. According to
the reported clinical data, three cases were examed for each type of valve device, 26-mm
CoreVavle and 26-mm SAPIEN 3, and listed in Table 2.1 and Table 2.2. Case 1
represents the labeled geometry of the device. Case 2 is the geometry with mean
ellipticity and expansion ratio. Finally, Case 3 is the worst-case scenario. It has the mean
values plus two standard deviations. The CoreValve was defined at three levels: inflow,
the nadir of leaflets, and central coaptation. In contrast, the SAPIEN 3 device is described
with three different levels: Inflow, mid-level, and outflow.
Table 2.1 Long and short diameters of 26-mm CoreValve device at different levels.
(SD: standard deviation)
Long TAV Diameter

Short TAV Diameter

(mm)

(mm)

26-mm
Medtronic

Nadir of

Central

leaflets

coaptation

26.0

24.0

22.0

Inflow

CoreValve
Case 1

Labeled
geometry

Nadir of

Central

leaflets

coaptation

26.0

24.0

22.0

Inflow

Case 2

Mean

24.5

23.4

22.1

19.6

19.8

20.2

Case 3

Mean+2SD

20.4

23.5

21.7

13.4

16.9

18.1

31

Table 2.2 Long and short diameters of 26-mm SAPIEN 3 device at different levels.
(SD: standard deviation)
Long TAV Diameter

Short TAV Diameter

(mm)
26-mm
Edwards SAPIEN 3
Case 1

Labeled
geometry

(mm)

Inflow

Mid

Outflow

Inflow

Mid

Outflow

26.0

26.0

26.0

26.0

26.0

26.0

Case 2

Mean

27.4

25.9

27.6

25.9

24.5

26.3

Case 3

Mean+2SD

25.6

23.5

25.5

22.7

21.2

23.6

2.3.1.1

Pulse Duplicator

The pulse duplicator testings were conducted to obtain the experimental data.
Customized washers were created by a Formlabs Form 2 SLA 3D printer (Formlabs, Inc.,
Somerville, MA) to test the valve devices in different configurations listed in Table 2.1
and Table 2.2. The schematics of the washers are shown in Figure 2.2 and Figure 2.3.
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Figure 2.2 Washer schematic for elliptically deployed 26-mm CoreValve

Figure 2.3 Washer schematic for elliptically deployed 26-mm SAPIEN 3
The elliptical 26-mm CoreValve and SAPIEN 3 in the washers are shown in Figure
2.4. The washers were created based on specifications in Table 2.1 and Table 2.2. To
improve the sealant between the TAV device and the washer, Teflon was used. It was
applied on the ridge of the washer in the three CoreValve cases, and it was wrapped
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around the washer's interior and external walls before the SAPIEN 3 device was
mounted. One elliptical orientation was applied in the experimental setting since the
opening area does not change when the ellipse orientation changes.

Figure 2.4 CoreValve and SAPIEN 3 devices mounted in the customized washers
(CoreValve on the top row and SAPIEN 3 on the bottom row)
The prepared TAV mounted washers were then tested in the pulse duplicator system
(BDC Labs, Wheat Ridge, CO) to mimic the normal physiological conditions. The testing
conditions were considered based on the ISO-5840 recommendations, the testing
standard for the prosthetic heart valve, such as 70 BPM, 100 mmHg mean aortic pressure,
and 5 L/min cardiac output. In order to mimic the blood at 37 ℃ in the body in the invitro environment, the glycerin (99% glycerin, The Science Company, Denver, CO,
USA) and phosphate-buffered normal saline solution (PBS 100 ml tablets, Research
Products International, Mount Prospect, IL) were mixed by volume ratio of 45% / 55%.
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The density of the running solution is 1.12 g/cm3, and its viscosity is 3.45 cP. The
testing conditions were controlled by manipulating the pulsatile pump speed, local
compliance, and peripheral resistance in the system. The flow rate at the aortic side was
recorded using an electromagnetic flowmeter (Carolina Medical Electronics, East Bend,
NC). The aortic and ventricular pressures were recorded using two strain gauge pressure
transducers (Utah Medical Products, Midvale, UT). The ten continuous cardiac cycle data
were recorded during the pulse duplicator testings. Additionally, the leaflet motion was
captured at 480 fps and 960 fps by a high-speed camera (Sony DSC-RX10M3) from the
top of the aortic valve.
2.3.2

Computational Simulation

2.3.2.1

Geometry Construction

The geometries of the 26-mm CoreValve and SAPIEN 3 leaflets were obtained using
a 3D laser scanner (NextEngine, Inc., Santa Monica, CA) at the resolution of 100 μm.
The thicknesses of the leaflets and the stent dimensions in the two devices were measured
with a Mitutoyo Digital caliper (Mitutoyo Corp, Kanagawa, Japan). The average
thickness was 0.43 mm for the 26-mm CoreValve device and 0.32 mm for the 26-mm
SAPIEN 3 device. The stent strut thickness and width were recorded as 0.5mm and 0.5
mm, respectively, for the 26-mm CoreValve, while the thickness/width for the 26-mm
SAPIEN 3 valve was 0.5/0.35 mm. The leaflet geometries were reconstructed in
Geomagic Design X (3D Systems, Littleton, CO). The stents of the TAV devices were
created and assembled with the leaflets and skirts in SOLIDWORKS (Dassault Systèmes,
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Waltham, MA) software packages. The assembled TAV geometries in SOLIDWORKS
are shown in Figure 2.5.

Figure 2.5 Geometry constructed in SOLIDWORKS
2.3.2.2

Mesh

The IGES files of the TAV devices' geometries were exported from SOLIDWORKS
and subsequently imported to HyperMesh (Altair Engineering, Inc., Troy, MI) for
meshing. The mesh independence studies for each valve type were evaluated; the detail
can be found in 8.3. The meshes created for this simulation are shown in Figure 2.6.
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Figure 2.6 Mesh generated in HyperMesh
2.3.2.3

Simulation Setup

The mesh was imported to ABAQUS/Explicit solver for FE simulation. The leaflet
and the skirt of the CoreValve device are made of one piece of porcine pericardium
material. The material of the leaflet was studied in the previous study106. A fung
anisotropic hyperelastic model was used. Since the anisotropic hyperelastic material
properties are associated with the material orientation, the material orientations for each
element were created in a homemade MATLAB code. Inside one S4 element, the first
orientation direction was assigned along the two unlinked edges. The second orientation
was assigned to the edges orthogonal with the first set of edges. Furthermore, the third
direction is applied along the normal direction of the element. The leaflet density was
considered to be 1100 kg/m3 107. The stent of the CoreValve device is made of a
superelastic material, nitinol alloy. The material properties have been analyzed by
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Finotello et al.108. Meanwhile, the SAPIEN 3 cobalt-chromium stent was also evaluated
by Bosi et al.109. The detailed values for the stents’ material properties were presented in
8.2. Moreover, the skirt in the CoreValve device is made from one piece of porcine
pericardium, while the skirt SAPIEN 3 valve device is made of Dacron.
A general contact was applied to all components to introduce the contact. The “TIE”
function was used on the relevant nodes to prevent the relative movement between
leaflet, skirt, and stent. There were two steps in the simulation. In the first step, the valve
devices were deformed to the specific dimensions listed in Table 2.1 and Table 2.2. After
the valve reached the desired dimensions, the external surface of the valve device was
fixed at six degrees of freedom. The two cardiac cycle pressure gradient curve was
applied on the leaflet surface in the second step.

Figure 2.7 “TIE” function applied to the mesh
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2.4

Result
The 26- mm CoreValve and 26-mm SAPIEN 3 valves were mounted on the

corresponding washers and tested in the pulse duplicator system based on the conditions
listed in Table 2.1 and Table 2.2. The mean transvalvular gradient for the 26-mm
CoreValve device obtained from the experimental data were 10.68 ± 0.12, 17.73 ± 0.22,
and 21.98 ± 0.10 mmHg for Case 1, Case 2, and Case 3, respectively. The 26-mm
SAPIEN 3 valve device testing result presented a result of 7.54 ± 0.14, 14.57 ± 0.32, and
18.22 ± 0.16 mmHg for Case 1, Case 2, and Case 3, respectively. The obtained pressure
gradient curves for the six cases are presented in Figure 2.8.
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Figure 2.8 Pressure gradient curve obtained from the pulse duplicator testings
At the same time, the leaflet motions were recorded during the experiment. They
were subsequently compared with the result of the simulations. The result of the leaflet
motion comparison is shown in Figure 2.9. There is a good agreement in leaflet motion
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between the experiments and simulations. The detail of the radial nodal locations at
different time points in one cardiac cycle is plotted in Figure 2.10 and Figure 2.11.

Figure 2.9 The leaflet motion comparison between the experiment and the simulation.
According to the CoreValve results in Figure 2.10, a delay is observed in the bottom
leaflet during the closing phase. The delay is 45 ms in Case 2 and 73 ms in Case 3.
Additionally, the coaptation height of the CoreValve device is increased in the elliptically
deployed geometries—the coaptation height increases as the eccentricity increases.
Moreover, the SAPIEN 3 leaflet motion shown in Figure 2.11 indicates that the
leaflet movements in Case 1 and Case 2 are comparable. Whereas the leaflet in Case 3
took less time from fully opened configuration to complete closure. The comparison in
Figure 2.9 indicates the same trend in the experiments.
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Figure 2.10 The 26-mm CoreValve leaflet radial nodal coordinate during one cardiac
cycle for three cases evaluated.

Figure 2.11 The 26-mm SAPIEN 3 leaflet radial nodal coordinate during one cardiac
cycle for three cases evaluated.
Following the validation by comparing the leaflet motion in experimental data and
simulation, the stress and strain were analyzed. The maximum in-plane principal stress of
the CoreValve leaflets from the isomeric view and top view were plotted in Figure 2.12.
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The stress at the commissure was 0.13 MPa for Case 1, 2.94 MPa for Case 2, and 4.21
MPa for Case 3. The overall stress increased in Case 2 and Case 3. High-stress regions
are primarily located near the valve device's fixed edge in elliptically under-expanded
cases. The histograms of the max in-plane principal stress value were plotted in Figure
2.13. The percentage of the number of elements within a specific stress value region was
plotted to quantify stress distribution. The mesh was meshed by specifying uniform
element edge size. The percentage value in the histogram plot can represent the
percentage surface area on the leaflet by assuming the elements have identical surface
areas. According to the histogram, the average maximum in-plane principal stress value
increases as the ellipticity increases. Additionally, the standard deviation of the stress also
increases in eccentric conditions. The maximum in-plane principal strain has the same
trend as the maximum in-plane stress. The high strain values were mainly located at the
connection between the stent and the leaflet fixed edges.
The comparison of SAPIEN 3 valve cases was plotted in Figure 2.16, Figure 2.17,
Figure 2.18, and Figure 2.19. The maximum in-plane principal stress and strain at 100
mmHg during diastole were analyzed. The average maximum in-plane principal stress
value at the commissures was 0.88 MPa, 1.36 MPa, and 1.96 MPa for Case 1, Case 2, and
Case 3. Figure 2.16 is the stress contour for the three cases. The high-stress value regions
were located at the leaflets’ fixed edges. Although the stress contours were similar
between the three cases, the average stress value increases in the eccentric frame
conditions. The largest standard deviation happened in Case 3. The max in-plane
principal strain values in Figure 2.18 exhibited the same distribution on the leaflets with
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stress. The average value and standard deviation have the same trend as the stress. Both
of them have a positive correlation with ellipticity value.

Figure 2.12 Maximum in-plane principal stress contours of CoreValve leaflets at 100
mmHg during diastole.
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Figure 2.13 Maximum in-plane principal stress histograms of CoreValve leaflets at
100 mmHg during diastole.
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Figure 2.14 Maximum in-plane principal strain contours of CoreValve leaflets at 100
mmHg during diastole.
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Figure 2.15 Maximum in-plane principal stress histograms of CoreValve leaflets at
100 mmHg during diastole.
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Figure 2.16 Maximum in-plane principal stress contours of SAPIEN 3 leaflets at 100
mmHg during diastole.
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Figure 2.17 Maximum in-plane principal stress histograms of SAPIEN 3 leaflets at
100 mmHg during diastole.
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Figure 2.18 Maximum in-plane principal strain contours of SAPIEN 3 leaflets at 100
mmHg during diastole.
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Figure 2.19 Maximum in-plane principal strain histograms of SAPIEN 3 leaflets at
100 mmHg during diastole.
According to Figure 2.1, the horizontal type 0 bicuspid aortic valve and the type 1
bicuspid aortic valve are likely to constrain the TAV devices in another direction. The
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elliptical shape's short axis and long axis are switched in this scenario. As a result, the
compression direction on the TAV devices is along with one of the gaps.
The maximum in-plane principal stress and strain of the CoreValve device under 100
mmHg during diastole are shown in Figure 2.20 and Figure 2.21. Similar to the first
constrain direction result, both stress and strain increase on the leaflet near the fixed edge
as the ellipticity increases. The SAPIEN 3 valve device's maximum in-plane principal
stress and strain results are presented in Figure 2.22 and Figure 2.23. Likewise, the stress
and strain are increased in elliptical deployment.

Figure 2.20 Maximum in-plane principal stress contours of CoreValve leaflets at 100
mmHg during diastole when short-axis aligned with one of the gaps.
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Figure 2.21 Maximum in-plane principal strain contours of CoreValve leaflets at 100
mmHg during diastole when short-axis aligned with one of the gaps.

Figure 2.22 Maximum in-plane principal stress contours of SAPIEN 3 leaflets at 100
mmHg during diastole when short-axis aligned with one of the gaps.
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Figure 2.23 Maximum in-plane principal strain contours of SAPIEN 3 leaflets at 100
mmHg during diastole when short-axis aligned with one of the gaps.
2.5

Discussion
The bicuspid aortic valve is the most common congenital aortic valve defect. The

patient with a bicuspid aortic valve usually experiences aortic stenosis at a younger age.
In order to apply the TAVR in low-risk patients, the TAV device needs to have
comparable durability in bicuspid aortic valve patients. The previous study evaluated the
impact of the ellipticity deployed balloon expandable intra-annular bioprosthesis when
the valve device is deployed with a high ellipticity index (long/short TAV diameter) up to
1.4. However, the clinical data has not observed such high ellipticity on the balloonexpandable valve device. This high ellipticity was found in the self-expandable valve
devices. However, the CoreValve is a supra-annular device, and the high ellipticity is
mainly located between the annulus level and the inflow level. The goal of this study was
to determine the eccentric and incomplete deployment of the bioprostheses in bicuspid
aortic valve patients through experimental testing and computational simulations.
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The result presented in this study indicated that despite the fact that CoreValve is a
supra-annular design, the eccentric and under-expanded CoreValve device could result in
altered stress and strain distribution on the leaflet during a normal cardiac cycle. The
stress and strain values on the leaflet of average deformed configuration (Case 2) and
severely deformed configuration (Case 3) were considerably higher than the fully
expanded configuration. Over time, the high stress and strain on the leaflet can lead to
tearing and material fatigue. It can reduce the valve durability, which is particularly
important for patients of younger ages. Although the results were based on the
computational simulations, the post-procedural balloon dilation should be considered for
the self-expandable valve devices to reduce the ellipticity and increase the expansion
ratio.
SAPIEN 3 valve device is a balloon-expandable device. It had slight stress and strain
change in the eccentric incomplete expansion cases. The leaflet motion observed in Case
2 and 3 matches with the result found in the previous study regarding the under
expansion’s impact on the SAPIEN 3 valve device110. This similarity indicates that the
balloon-expandable intra-annular design, SAPIEN 3, is dominated by the under
expansion in the bicuspid aortic valve patients. The high stress and strain on the
connection between the leaflet and skirt demonstrate that the tear may happen at that
location under cyclic loading.
The result from this study proves that the eccentric and incomplete deployment of the
TAV devices in bicuspid aortic valve patients will lead to impaired leaflet kinematics. It
can potentially lead to increased blood stasis on the leaflets. A previous study has found
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an increased blood stasis time on the incomplete expanded SAPIEN 3 valve device at the
fixed edge110. According to the leaflet motion observed in this study, increased blood
stasis is likely to happen on the TAV devices following the implantation in the bicuspid
aortic valve patients. The increased blood stasis promotes the contact risk between the
activated platelets and blood components, which accumulate and form thrombosis on the
leaflets. The accumulated thrombosis could lead to the risk of HALT and HAM77,111-113.
Additionally, the distorted leaflet coaptation in the elliptical under-expanded TAV device
can increase the risk of patient-prosthesis mismatch114.
There are several limitations within this study. Firstly, this study used group-average
data to analyze the synergistic impact of the eccentric and incomplete expansion of the
valve device in bicuspid aortic valve patients. The patient-specific data could be
significantly different from the group average data, even though the clinical data-based
results can provide insight into what may happen in the clinical trials. Secondly, the
conditions analyzed in this study are idealized. Since the morphology of the bicuspid
aortic valve varies from patient to patient, the location and orientation of raphes on the
bicuspid aortic valve can alter the geometry. However, this study assumed the device is
deployed with two leaflets symmetrically positioned. In addition, both TAV devices
evaluated in this study are not the most recent generation devices. Future studies may
focus on the newer generation TAV devices to determine if the problems observed in this
study still exist. Finally, the pulse duplicator testings system was designed for pressure
measurement. The kinematics of the leaflet were recorded manually with a camera, which
might not align well with the top view of the valve device. The accuracy of the recorded
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leaflet kinematics through the experiment is not reliable. It can only be used for general
comparison. Future studies are proposed to assess the relation between blood stasis and
impaired leaflet kinematics.
2.6

Conclusion
In conclusion, this study investigated the eccentric and incomplete deployment of the

TAVs in bicuspid aortic valve patients. The results indicate that the elliptically underexpanded geometry can impair the leaflet kinematics and alter the stress and strain
distributions. The self-expandable device is more likely to have reduced durability in
bicuspid aortic valve patients. It could potentially lead to an increased risk of thrombosis
and material fatigue. Post-procedural balloon dilation could be advantageous in
alleviating the leaflet distortion and high stress and strai
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Chapter Three: Regional Under-expansion of Transcatheter Aortic Valve devices
following Transcatheter Aortic Valve Replacement
3.1

Overview
TAVR has become commonly used in patients with symptomatic AS and not eligible

for open-heart surgery. However, the local geometry around the aortic valve varies from
patient to patient. The different constraints in the body could prevent the valve device
from deploying in the designed shape. When the constrain is unevenly distributed, the
valve device can be deployed into regional under-expanded geometry.
3.2

Background
Regional TAV device underexpansion has been found to be the potential lead to the

increased risk of leaflet thickening. The regional underexpansion happens more
frequently on the self-expandable valve devices. Fuchs et al.115 researched several
common self-expandable valve devices, including Medtronic CoreValve, CoreValve
Evlout R series devices (Medtronic, Minneapolis, MN, USA), and Portico (St. Jude
Medical, St. Paul, MN, USA). They found that the Moderate-to-Severe underexpansion
(≤90º) of the transcatheter aortic valve device has a high incidence of leaflet thicking
when compared with the evenly expanded device (120º). This regional underexpansion
phenomenon happens in both self-expandable valves and balloon-expandable valves116.
The washout time and the leaflet angle have a negative relation. The reduction of leaflet
angle can lead to an increase in blood washout time116. Those studies revealed a
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relationship between leaflet expansion angle and leaflet kinematics. This study aims to
analyze the leaflet kinematics and the mechanical impact on the leaflet following regional
underexpansion of the self-expandable valve device using a simulation approach.
3.3

Method
3.3.1

Experimental Setup

A self-expandable 26-mm CoreVavlve was used to evaluate the expansion angle’s
impact. The regional under-expanded self-expandable devices were examed by Fuchs et
al.115. The underexpansion angle was defined as the angle formed by the stentcommissure connections and center of the valve device. According to the clinical data,
the regional under-expanded geometry was divided into several categories, severe(<78º),
moderate(78º to 90º), mild(90º to 102º), and trivial(102º to 114º).
Since the regional underexpansion observed in the clinical data was between 90° and
120°, four cases were studied and shown in Table 3.1. The under-expanded leaflet was
marked as red, and the other two leaflets were located symmetrically with blue and green
color marks. Case 1: the geometry expanded to the designed shape; Case 2: 90% overall
expansion with evenly expanded leaflets; Case 3: the mild condition (90% overall
expansion with 102º expansion on the small-angle cusp); Case 4: the moderate-to-severe
condition (90% overall expansion with small-angle cusp expansion angle ≤90º). Case 2 to
4 were considered together with overall expansion because the regional underexpansion
is usually associated with overall under expansion. 90% overall expansion was
considered as the average expansion ratio117. The narrowed region was located in the
valvular region. Thus, the region underexpansion was applied from the bottom of the
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valve device to the nadir of the leaflet. The region from the nadir of the leaflet to the
commissure level was released to the designed expansion angle with a linear increase
gradient.
Table 3.1 Four expansion conditions analyzed in this study
Table 1

Case 1

Case 2

Case 3

Case 4

Overall
Frame
Expansion

100%

90%

90%

90%

Regional
Frame Underexpansion

None

None

Mild

Moderate

Schematic
Drawing

Figure 3.1 Four-layer washer used in the experiment.
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A customized washer was created to crimp the 26-mm CoreValve device to the
specified location to realize the conditions in the proposed cases. The washer consists of
four layers and four pins. The four layers components were 3D printed in ABS material
with a U-Print SE Plus 3D printer (Stratasys Ltd., Eden Prairie, MN). The pins used were
made from steel wires. The top and third layers have two symmetric components each
layer. One pin was printed on the inner wall of each component to control the movement
of the valve device. During the crimping phase, the valve device was fitted into the
washer. The nadir of the leaflet level was aligned with the top surface of the washer. The
bottom of the valve device fits with the third layer of the washer from the top.
Subsequently, the pins push against the stent frame to deform the stent to the
specified location. When the valve reached the desired location, four pins were inserted
in the holes on the washer to assemble the four layers. Following this procedure, Teflon
was used to wrap around the assembled washer and 26-mm CoreValve device to prevent
paravalvular leakage. The assembled washer and 26-mm CoreValve are shown in Figure
3.2. The top row is the top view of Case 2, Case 3, and Case 4. The bottom row exhibits
the bottom view of the three cases. In Case 2, the constrain from the pins was not applied
to the valve device, so that only 90% overall expansion was considered for that case.
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Figure 3.2 The leaflet in the washer from Case 2 to Case 4. (top: the top view from
the assembly; bottom: the bottom view of the assembly)
The assembled washers were then put in the pulse duplicator system at the aortic
location to conduct the in-vitro test. Similar to the pulse duplicator testing setup in
Chapter Two: The in-vitro testing was set up based on ISO 5840 recommendations, such
as 70 BPM, 100 mmHg mean aortic pressure, and 5 L/min cardiac output. The working
fluid in the pulse duplicator was glycerin and normal saline solution mixture at a volume
ratio of 37%/63%. During the testing, the pressure was recorded with transducers at the
aortic and ventricular locations. The flow rate at the aortic position was also recorded
simultaneously.
3.3.2

Simulation

3.3.2.1

Geometry

The geometry of the 26-mm CoreValve device was obtained in the previous chapter.
The leaflet geometries were acquired in the 3D laser scanner (NextEngine, Inc., Santa
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Monica, CA). Since the 3D scanner can not capture the stent geometry due to the laser
reflection on the stent, we reconstructed the stent geometry by measuring the thickness

of the leaflets using the Mitutoyo Digital caliper (Mitutoyo Corp, Kanagawa, Japan).
The measured thickness was 0.43 mm. The stent struts were 0.5mm in thickness and 0.5
mm in width. The leaflet geometry was reconstructed in Geomagic Design X (3D
Systems, Littleton, CO). The stent geometry was created based on the measurements in
SolidWorks (Dassault Systèmes, Waltham, MA).
3.3.2.2

Mesh

The mesh was created in HyperMesh (Altair Engineering, Inc., Troy, MI), and mesh
independence was checked in the previous chapter. In this study, the mesh of the leaflet
and skirt were refined near the nadir of leaflets. The refinement minimized the crimping
impact when compressing the valve device to the regional under-expanded shape. The
leaflet and skirt were meshed together as one continuous mesh with S4 elements. The
number of elements was 7944 and 8610 on the leaflets and skirt mesh, respectively. The
stent was meshed with 15580 C3D8 elements, the same number of elements as the
previous study. Subsequently, the mesh was transferred to ABAQUS/Explicit solver for
the FE simulation.
3.3.2.3

Simulation Setup

The material properties of each component were the same as the material properties
defined in the previous chapter106. According to the previous studies, the density of the
bovine pericardium was defined as 1100 kg/m3. The material of the leaflet and skirt
elements were assigned with the fung anisotropic hyperelastic material properties.
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Subsequently, the material orientations were obtained for each element using a
homemade MATLAB function to describe the fiber orientation on the leaflets. The
superelastic material properties were defined on the stent108. The contact between the
exterior skirt and stent interior surfaces was defined with the TIE function to mimic the
suture between the skirt and stent.
There were two steps in the simulations. In the first step, displacement control was
applied to the stent to deform the stent to the specified configurations from Table 3.1.
Subsequently, the stent nodes were fixed in six degrees of freedom in the second step.
Two cardiac cycles of time-dependent pressure obtained from the pulse duplicator
testings were applied to the leaflets. Strain, stress, displacement, and coordinate were
recorded every 0.2 millisecond to capture the whole simulation precisely.
3.4

Result
The simulations were validated with the experimental data. The side-by-side

comparisons were shown in Video 8.2. The movement of the leaflets at several specific
time points, opening, the peak of systole, closing, and the peak of diastole in the four
cases, were shown in Figure 3.4. The Gorlin equation was used to calculate the effective
orifice area of the valve device.
The experiment result showed that the mean transvalvular pressure gradient and the
effective orifice area are 7.5 ± 0.16 mmHg and 1.72 ± 0.03 cm2, respectively, for Case 1.
Whereas the under-expanded cases have a similar mean transvalvular pressure gradient.
They are 27.9 ± 0.3, 27.5 ± 0.3, and 28.00 ± 0.2 mmHg for Case 2, Case 3 and Case 4.
The pressure gradient curve obtained from the pulse duplicator testing for Case 2, Case 3,
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and Case 4 are shown in Figure 3.3. The effective orifice area was found to be 1.21 ±
0.06, 1.25 ± 0.02, and 1.12 ± 0.11 cm2 in Case 2, Case 3, and Case 4.

Figure 3.3 The pressure gradient curve for Case 2, Case 3, and Case 4
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Figure 3.4 The leaflet kinematics comparison between four cases. (Case 1: fully
expanded geometry; Case 2: the geometry with 90% expansion ratio; Case 3: 90%
expanded device with 102° expanded right leaflet; Case 4: 90% expanded device with 90°
expanded right leaflet)
A cylindrical coordinate system was applied, and the leaflet nodal coordinate at four
different time points, opening, the peak of systole, closing, and the peak of diastole, were
shown in Figure 3.4. It indicates that overall underexpansion and regional
underexpansion can impair the leaflet motion. The 90% evenly expanded CoreValve
(Case 2) had a similar motion to the fully expanded device (Case 1). However, the
maximum opening of the leaflet was reduced in Case 2. A considerable delay was
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observed on the cusp larger than 120° (Case 3 and Case 4). The delay increases as the
regional underexpansion get severe. The delay on the large angle cusp is highest in Case
4. Video 8.1 shows the comparison between the experimental result and the simulation
result. Comparable leaflet motions were found in the four cases during the normal cardiac
cycle. The video indicts that the small-angle leaflet could not be fully expanded.
The maximum in-plane stress was evaluated following the FE simulation and shown
in Figure 3.5. The average maximum in-plane stress at commissures was 0.14, 0.19, 0.26,
and 0.32 MPa for Case 1, Case 2, Case 3, and Case 4, respectively. According to the
comparison between Case 1 and 2, high stress was introduced to the commissure level
when the valve device was under-expanded evenly. Whereas, in the regional underexpanded cases, Case 2 to 4, the high-stress regions were mainly located at the fixed
edge. The small-angle leaflet had the highest stress value within the valve device, and the
stress increased as the angle decreased.
Histograms of the maximum in-plane principal stress were created to evaluate the
stress distribution in different leaflets. The percentages in the histograms were calculated
by dividing the number of elements within the value range by the leaflets’ total number
of elements. Figure 3.6 is the histogram for the small-angle leaflets. Based on the plot,
the mean stress value increases as the angle of the leaflet decreases. The range of the
stress is also expanded when the leaflet angle decreases. However, Figure 3.7 indicates
that the average stress value and range on the two symmetrically located large-angle
leaflets remain almost the same in 90% overall under-expanded cases, Case 2 to 4.
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Figure 3.5 Maximum in-plane principal stress at 100 mmHg during diastole.
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Figure 3.6 Histogram of maximum in-plane principal stress on the small-angle leaflet
at 100 mm Hg pressure during diastole.
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Figure 3.7 Histogram of maximum in-plane principal stress on the two large-angle
leaflets at 100 mm Hg pressure during diastole.
3.5

Discussion
TAVR has become a well-established procedure to replace the malfunctioned aortic

valve. The device is delivered to the stenotic location via a catheter without removing the
calcified leaflet. Therefore, the TAV deployment is highly dependent on the local
geometry at the annulus shape and the calcification at the native valve. During the TAVR
procedure, the TAV devices are usually oversized than the annulus to minimize the
paravalvular leakage. Therefore, both overall under expansion and regional under
expansion were observed in patients with a highly calcified aortic valve following
TAVR. Clinical data showed that the self-expandable valve devices have a higher risk of
the regional frame under expansion than balloon-expandable devices102,103.
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Despite the promising outcomes following TAVR, concerns like leaflet thrombosis
are still associated with this procedure. Up to 40% of the TAVR patients reported having
subclinical leaflet thrombosis following TAVR77,111. It has been found that the subclinical
leaflet thrombosis risk is higher in TAVR than in surgical aortic valve replacement77. The
earliest HALT can be observed 30 days following TAVR118. The local environment in the
patient and the device geometry are associated with thrombosis formation. In the
previous study, the TAV devices with overall underexpansion were likely to have a
higher risk of thrombosis due to the increased blood stasis time110. Midha et al.19 found a
higher thrombosis risk in patients with under-expanded SAPIEN 3 valve devices.
However, the other group reported that the blood washout was improved in the underexpanded CoreValve and SAPIEN 3119. Therefore, studies need to be conducted to
evaluate the effect of the overall TAV under-expansion on thrombosis. Additionally,
regional incomplete expansion is observed together with the overall under-expansion in
valve devices due to complex geometry near native valve115,116.
This study aimed to analyze kinematics and mechanical effect on the self-expandable
valve following overall underexpansion and regional incomplete expansion to assess the
durability of the valve device. The result from this study indicated that the regional
incomplete expansion of the TAV stent impairs leaflet kinematics. The small-angle cusp
(cusp angle<120° in Case 3 and 4) could not be fully expanded. The incomplete
expansion also leads to the distortion of the leaflet. The reduced range of motion and the
distorted leaflet geometry can potentially increase the blood stasis on the leaflet surface,
further raising the thrombosis risk120. Fuchs et al.115 observed that the regional TAV
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under expansion was linked with HALT in clinical data. The risk is potentially higher in
intra-annular TAV design than the supra-annular design113,115. It can be hypothesized that
the post-procedural balloon expansion following the implantation of the self-expandable
valve device and supra-annular positioning can alleviate the thrombosis risk. However,
further study is needed to validate the finding.
The stress value and its distribution on the leaflet were also evaluated in this study.
The high stress is induced in the commissure region when the valve device is overall
under-expanded. The same trend was also found in the previous studies about the
balloon-expandable valve device with overall under-expansion121,122. The increased stress
on the commissure region could introduce accelerated valve degeneration, reducing the
valve device's durability. In addition to the overall under-expansion, the result from this
study pointed out that regional underexpansion also induced high stress on the fixed edge.
There stress increases as the angle of the leaflet decreases. The histogram indicates the
average stress is lower on the large-angle cusps (cusp angle >120°) when compared with
the small-angle cusp. The stress stays relatively the same when the angle increases.
However, the small-angle cusp is highly associated with the angle. The smaller angle will
induce higher stress on the leaflet. Thus, material fatigue is likely to happen on the smallangle leaflet in the regionally under-expanded valve device. The limited valve durability
could be a major factor preventing the device from being used in low-risk patients.
There are limitations in this study that could be a potential improvement direction in
future studies. Firstly, the current project is based on group-average data instead of
patient-specific data. The native environments are usually more complex than the
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presented cases. The calcification, annulus shape, valve positioning, and oversizing could
alter the finally deployed shape. The clinical research showed that the regional underexpansion is also associated with unevenly deployed frame height116. Although this study
only considered the overall expansion ratio and the regional under-expansion, it provided
an insight into the impact of the regional under-expansion on leaflet kinematics and
structural characteristic in general aspects. It is helpful for us to find out the potential risk
of subclinical leaflet thrombosis and the material fatigue location. Additionally, this study
only conducted the structural analysis on the device. Future studies are motivated to use
fluid-solid interaction simulations to assess the hemodynamics impact of the regional
under-expanded TAV device on thrombosis formation.
3.6

Conclusion
To sum, the regional under-expanded geometry could impair the kinematics of the

leaflet and induce high stress on the cusps with an angle smaller than 120°. The limited
motion on the leaflet could increase the blood stasis in the neo-sinus region, which will
lead to a higher risk of thrombosis. The localized high stress at the fixed edge of the
leaflet could accelerate the material fatigue, which will reduce the durability of the valve.
Therefore, post-procedural balloon dilatation could be a potential solution to alleviate the
impact of leaflet distortion and increased stress.
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Chapter Four: Thrombosis Formation Risk Analysis of Supra-annular
Transcatheter Aortic Valve Device: A Simulation Approach
4.1

Overview
The previous study has shown that the supra-annular design, like CoreValve, has a

high thrombosis risk when implanted with a lower depth19. However, the risk of
thrombosis on the leaflet has not been investigated. This study aimed to assert the
thrombosis risk in the supra-annular TAV devices. The investigation quantified the
leaflet’s BRT during normal cardiac cycles via implementing the one-way FSI approach.
4.2

Background
Leaflet thickening and immobility have been observed on bioprosthetic aortic valves

with high occurrence on the transcatheter valve devices77. HALT is usually associated
with this type of problem. The formation of HALT could increase the risk of stroke and
transient ischemic attack77. Although taking anticoagulation can reduce the risk of
thrombosis formation, the HALT could recure on the leaflet following the discontinuation
of the anticoagulation intake. The HALT could potentially impair the durability of the
valve device, especially the low-risk patient since they are expected to have a longer life
expectancy.
According to Virchow’s Triad, the blood residence time (BRT) is a potential risk
factor for thrombosis formation. Studies have shown that the intra-annular design has a
larger neo-sinus volume with more blood stasis than the supra-annular design123. Bench
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testing and computational simulation revealed that the high implantation location could
reduce the blood stasis in the neo sinus region 19,113,119.
BRT on SAPIEN 3 valve and the surgical valve has been studied in previous studies.
The SAPIEN 3 valve in patient-specific geometry was found to have an increased BRT
due to the confined geometry around the leaflet, whereas the surgical valve has a lower
chance of thrombosis 112. When compared with intra-annular and supra-annular
positioning, the supra-annular positioning of the SAPIEN 3 valve device was found to
have reduced BRT value113. CoreValve, as a supra-annular design, is hypothesized to
have a significantly lower blood stasis. However, the PARTNER 3 cardiac CT
Substudy124 showed the incidence of HALT with SAPIEN 3 valve at 28% after one year,
whereas the Evolut Low-Risk33 trial indicated the HALT rate of 30.9% following one
year. We hypothesize that the similar HALT rate is potentially caused by the TAV leaflet
design and leaflet kinematics.
Due to the limited optical access and optical distortion to the neo-sinus region, the invitro experiments were not able to provide a comprehensive result19. 2D PIV
measurement cannot capture the 3D experimental result at the neo-sinus region. The
other techniques, like dye injection, can only measure the average value for blood
washout from the neo-sinus region. The FSI technique allows us to estimate the result in
inaccessible regions. In this study, one-way FSI was used to conduct the simulation. The
downstream experimental and simulation data were compared to validate the simulation
result.
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4.3

Method
4.3.1

Experimental Setup

Similar to the previous chapters’ pulse duplicator setup, a customized washer was
created to hold the valve device in the pulse duplicator (BDC Labs, Wheat Ridge, CO,
USA) at its designed shape. The covered region is shown on the right-hand side in Figure
4.1. The covered leaflet height and TAV device height were 6 mm and 20 mm,
respectively. The experimental was set based on ISO 5840 recommendations. Glycerin
and normal saline solution were mixed at a volume ratio of 37%/63% to mimic the blood
in normal physiological conditions.
During the experiment, the pressure was recorded with strain gauge pressure
transducers (Utah Medical Products, Midvale, UT, USA). Meanwhile, the flow data were
captured by an electromagnetic flowmeter (Model 501, Carolina Medical Electronics Inc,
East Bend, NC, USA). While the experiment was running, a high-speed camera (Sony
DSC-RX10M3) was placed at the outlet of the pulse duplicator system to capture the
motion of the leaflet motion of the TAV device.
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Figure 4.1 The experimental setup (Left: pulse duplicator; Middle: the pulse
CoreValve in pulse customized washer; Right: 26 mm CoreValve device, the red
shadowed area is the washer covered region).
4.3.2

Simulation

One-way FSI simulations were carried out to evaluate the BRT on the leaflets. There
were two steps in the simulation. In the first simulation, the structural analysis of the two
valve devices was done in the ABAQUS/Explicit solver. Subsequently, the nodal
locations at each time step were exported to generate the frames for the leaflets by using a
homemade MATLAB code. The frames were then implemented in the CFD simulation in
the ANSYS Fluent by using a UDF. During the simulation, the meshes were re-meshed to
correspond to the leaflet location in ANSYS Fluent in each time step. The simulation
results were then input in Tecplot 2021 for post-processing.
4.3.2.1

Geometry

The structural analysis geometry was generated in SolidWorks after the pulse
duplicator testing. Only the leaflets' geometry was considered in the simulation to
simplify the FE simulation. The stent was simplified to a channel that follows the interior
diameters at different levels. For detail on the geometry, please refer to Chapter Two:.
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The geometry was constructed based on pulse duplicator testing in the computational
fluid dynamics (CFD) simulation. Figure 4.2 shows the iterations of the fluid geometry. It
started with the whole model (a), including the valve device, washer, and fluid domain.
After removing the solid components except for the leaflet, the whole model for the CFD
simulation was obtained in (c). Since the whole model was axial symmetric, one-third of
the model, shown in (d), was considered to reduce the computational cost.

Figure 4.2 Modeling of the CFD section in SolidWorks. (a) the 26 mm CoreValve
device with fluid volume and washer. (b) the model after removing the washer. (c) the
whole model for CFD simulation. (d) one-third of the CFD model.
4.3.2.2

Simulation Setup

The model was meshed in HyperMesh and input in ABAQUS/Explicit solver. The
material properties of different components were described in the previous chapter. Fung
anisotropic hyperelastic material properties were applied to the leaflet. The material
orientation for each element on the leaflet was defined using a homemade MATLAB
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function. Same with the previous structural analysis, the orientations have one direction
aligned with the free edge. The second direction is generated orthogonal with the first
direction on the element. The normal direction of the orientation was identical to the
individual element. Since the stent was made with Nitinol alloy, the material properties
were assigned with a superelastic material model. The stent external surface and the fixed
edge of the leaflets were fixed at six degrees of freedom throughout the simulation. The
symmetric planes of the valve devices were considered a rigid wall, which prevents the
leaflets from being excessively compressed. Two cardiac cycles of transvalvular pressure
gradient curve obtained from the pulse duplicator testing, which is Case 1 in the previous
studies, were applied uniformly on the leaflet elements.
In the CFD section of the one-way FSI simulation, one-third of the fluid geometry
mesh was created in Pointwise (Pointwise, Fort Worth, Texas). The k-ε model with the
second-order precision method was implemented. The top plane was defined as the
pressure outlet, and the bottom was defined as the pressure inlet. The two cardiac cycles
of the pressure gradient curve applied from the FE simulation were implemented on the
pressure inlet. The surfaces perpendicular to the inlet and outlet were assigned as
symmetric planes, while the leaflet and the external surfaces were considered walls with
non-slip boundary conditions in the simulation. The material properties of the fluid
domain were assigned with 1060 kg/m3 and 0.0035 kg/(m⋅s) to mimic the blood
(glycerin/normal saline solution in the experiment).
An Eulerian approach was used to quantify the BRT value. The residence time
donates as TR in the following equation113.
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𝜕𝜕𝑇𝑇𝑅𝑅
+ 𝒗𝒗 ∙ ∇TR = 1
𝜕𝜕𝜕𝜕

𝒗𝒗 in the equation is the flow velocity vector. This equation was solved simultaneously
with continuity and the conservation of momentum equations. A scalar was used to

quantify the BRT value in the region. It started from 0 s at the flow inlet, which is the
bottom surface of the model. The TR increases when the particle enters the region of
interest. The particles not entering the region of interest will be counted as 0125,126.
4.3.2.3

Mesh Independency Study

The mesh for the FE simulation was generated in HyperMesh and analyzed in the
previous study.

Figure 4.3 The mesh of the 26 mm CoreValve device for structural Analysis
CFD mesh model density was evaluated with three different mesh densities with a
simple transient problem. The pressure inlet was assigned with a ramped pressure
increased from 0 mmHg to 40 mmHg in 0.1 s. The final velocity magnitude result was
compared. Finally, the medium mesh density was chosen for the two cardiac cycle CFD
simulation. The detail of the mesh independence study is presented in 8.3.2.
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4.4

Result
During the pulse duplicator testing, the pressure and flow rate were recorded for 10 s

when it reached the target condition. The mean transvalvular pressure gradient obtained
was 7.5 ± 0.16 mmHg. According to the Gorlin formula, the corresponding valve
effective orifice area was 1.72± 0.03 cm2.
4.4.1

Leaflet Kinematics

The top view of the leaflet motion was presented in Video 8.3. Since the optical
access to the belly region of the experimental data was limited, the data was only
validated with the top view. A comparable leaflet motion was observed between the
simulation and experiment results throughout the cardiac cycle. The result from finite
element analysis was used to analyze the leaflet kinematics. The side view of the finite
element analysis was provided in Video 8.4. According to Video 8.4, the 26-mm
CoreValve has limited motion at the bottom of the belly region during systole. The
leaflet’s lower belly region could not reach the stent during systole. The red dashed circle
highlighted the region with limited motion.
The velocity magnitude at five critical points in the second cardiac cycle result was
plotted in Figure 4.4. The velocity magnitude contour at the middle plane of the fluid
domain is shown in the figure. During the acceleration phase, a high-velocity jet was
observed at the centerline. The highest velocity magnitude was located at the center of
the jet at peak flow. The corresponding jet had a diameter of approximately 17.7 mm.
Subsequently, the velocity magnitude dropped when the pressure decreased during the
deceleration phase of the diastole. Arbitrary massless particles illustrated the blood cells’
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movement in the region of interest (ROI). Initially, the particles reside in the neo-sinus
region. They started to move out of the ROI when the leaflet began to open. The particles
outside of the neo-sinus region were washed out quickly during systole. However, most
particles within the neo-sinus region remained inside the ROI until the peak of flow.
According to Video 8.5, most of the particles in the neo-sinus region barely moved
during the second cardiac cycle. Finally, at the end of the diastole, many particles
remained inside the neo-sinus region, which was the identical space covered by the
washer.

Figure 4.4 The velocity contour with particle movement at different time points in the
second cardiac cycle. The contours represent the velocity magnitude at the center of the
fluid domain.
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4.4.2

BRT

BRT result is shown in Figure 4.6. The result indicates that the BRT value built up at
the lower belly region when the leaflet closed. Low BRT values were located at the free
edge and the commissures, while the high BRT happened near the lower belly region
near the fixed edge, which has a limited leaflet movement. It has a good agreement with
the movement of particles. To quantify BRT on leaflets, BRT in the space between the
washer and leaflets, also known as the neo-sinus region, was presented in Figure 4.5 and
Figure 4.6. According to the contour, the BRT exhibits a slightly asymmetric distribution.
The BRT in the volume indicates that the volume was reduced during systole. During
diastole, BRT accumulated and reached the maximum value. The average BRT at the end
of the first cardiac cycle and the second cycle were 0.72 s and 0.73 s, respectively. The
majority of the blood was washed out after one cardiac cycle. However, the BRT near the
joint between the leaflet and washer interior wall accumulates over time. It reached the
maximum value at the end of the second cardiac cycle. The magnitude of maximum BRT
at the end of the second cycle was nearly doubled compared with the value at the end of
the first cycle.
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Figure 4.5 The BRT on the fully expanded 26-mm CoreValve device at five different
time points in the first cardiac cycle (top row: top view, middle row: front view of the
neo-sinus volume, bottom row: slice view of the neo-sinus)

Figure 4.6 The BRT on the fully expanded 26-mm CoreValve device at five different
time points in the second cardiac cycle (top row: top view, middle row: front view of the
neo-sinus volume, bottom row: slice view of the neo-sinus)
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The BRT at the end of diastole is presented in a histogram, Figure 4.7, to better
visualize the thrombosis formation risk. The BRT on the leaflet at the end of the second
diastole was mainly between 0.4-0.6s. There were 57.77% of the leaflet area had BRT
within this range. Only 17% of the area showed a BRT value larger than 1 s.

Figure 4.7 Histogram of the BRT on 26-mm CoreValve leaflet at the end of the
diastole.
4.5

Discussion
Subclinical leaflet thrombosis is observed following TAVR and could be a potential

risk factor that reduces the valve devices’ durability124. This study investigated the
likelihood of thrombosis formation on the supra-annular bioprosthesis valve by analyzing
the blood stasis on the leaflet in a pulse duplicator model. A limited leaflet belly region
motion was observed during the systole. It has a high coincidence with the high BRT
location. The velocity result with particle movement confirmed that the limited motion
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provides a channel with a low flow velocity. The platelets and platelet agonists are likely
to stay in that region and initiate thrombosis. This finding stays true for both rigid
calcified aortic valve and the valve-in-valve configuration since both create confinement
around the leaflets.
Midha et al. have found that the thrombosis volume in the patient with
CoreValve/Evolut Rs devices positively relates to the implantation depth19. The optimal
location of the valve leaflet is aligned with the highest point of the surrounding confined
surface. The confined geometry around the leaflet is unavoidable due to the implantation
recommendation. According to the device’s instruction, it is recommended to be
implanted 3-5 mm below the aortic annulus to reduce the permanent pacemaker
implantation127. Therefore, the high BRT area could be larger than the presented result.
However, the peak BRT value might be lower in the patient. Studies have shown that the
coronary arteries could promote the sinus region’s blood washout. Video 8.3 showed that
the structural simulation worked out well regarding capturing the kinematics of the
leaflet. Despite the limitation of the optical access in the experiment, Video 8.4 has
shown that the belly region of the CoreValve device has a limited motion on the lower
belly region of the leaflet when it is opening. It could potentially block the movement of
the blood cells from exiting the neo-sinus region. The particles’ movement in Video 8.5
and Figure 4.4 proved that the particles at the neo-sinus region had difficulty being
washed out of the confined volume. Those particles resulted in residence, which
prolonged the BRT on the lower belly region of the leaflet. The prolonged BRT is a risk
factor for thrombosis formation. According to Virchow Triad, blood stasis is one of the
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critical factors that cause thrombosis formation128,129. It promotes the platelets and
platelet agonists’ contact. When the concentration reaches the threshold, it could result in
thrombosis 130,131.
4.5.1

Clinical Implications

Although the newer generation has shown a promising outcome following the TAVR,
approximately one-third of the patients were found to develop HALT within one year,
according to clinical data from the Evolut Low-Risk trial and the PARTNER 3 cardiac
CT sub-study33,124. Thrombosis on the leaflet could lead to HALT and potentially cause
severe conditions, like stroke and heart attack. Ncho et al.132 have found that the shorter
leaflet length and higher implantation location could help alleviate the flow stasis in the
neo-sinus region. Although the implantation of the CoreValve device has a smaller neosinus region, the implantation depth recommendation still results in a neo-sinus region.
Therefore, the physician may need to find a way to reduce the neo-sinus region without
further reducing the implantation depth. Immanuel David et al. have found that
underexpansion of the valve device could reduce this risk119. However, other studies have
a contradictory opinion and believe the underexpansion could result in a higher stasis on
the leaflets110. This study indicates that the majority of the flow volume within the neosinus region can be washed out within one cardiac cycle during systole. However, the
stasis is high in the lower belly region due to the limited motion of the leaflet. This
observation may explain why the experiments showed an excellent washout result while
HALT was still observed in the patients following TAVR. The experimental method,
such as dye injection, can only provide the average blood washout value, but there was a
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certain amount of blood trapped in the small region and experiencing a high stasis time.
A further clinical study may target finding the fundamental cause of the thrombosis in
patients who received supra-annular TAV devices.
4.5.2

Limitation

There were some limitations in this study. One major limitation is that the model has
simplified to 1/3 of the whole geometry instead of the whole model. It can provide the
result on one leaflet within a reduced time. However, the result on the other two leaflets
might be slightly different due to the turbulent flow in the field.
Additionally, some parameters were idealized. The implantation depth was placed at
3 mm lower than the annulus and did not displace along the flow direction when the
pressure was applied. In reality, the valve device is not firmly fixed at the location. Some
of the paravalvular leakages can happen at that location due to this reason. This model
was based on the geometry of the customized pulse duplicator. It does not have left and
right coronary arteries. The flow in this model only has one pressure inlet and one
pressure outlet. Without the additional two flow outlets at the annulus, the flow profile
could not fully represent the result in the patient. Further study using the patient-specific
geometry could reveal the effect of the coronary arteries. The additional radial direction
flow could potentially relieve the blood stasis in the neo-sinus region.
4.6

Conclusion
This study provided the physicians' insights into why the thrombosis risk of supra-

annular design valve device is similar to the surgical valve device, while the fluid
mechanics study indicates the supra-annular positioning is supposed to have better blood
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wash out. However, the BRT at the lower belly region is unavoidable. Future design
improvements should pay more attention to the lower belly region. A design with better
kinematics could improve the blood washout and reduce the thrombosis risk.
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Chapter Five: Hemodynamic Analysis and Comparison of Transcatheter Aortic
Valve Devices
5.1

Overview
In order to determine thrombosis risk on TAV after the procedure, hemodynamics on

TAV leaflets need to be asserted. This study aimed to analyze the hemodynamics of
intra- annular TAV design and compare the thrombosis risk of intra-annular and supraannular designs after ViV by quantifying the blood stasis time on the newly implanted
TAV device leaflets. This study was conducted by analyzing the flow pattern in the pulse
duplicator. It was done by comparing the flow profiles with the particle imaging
velocimetry (PIV) for validation.
5.2

Background
Although TAVR has been a well-established approach to treating the patient who has

received SAVR, there is an increasing concern regarding the complications such as
thrombosis on the valve leaflets, especially on the TAV leaflets133-136. Increased
thrombosis formation is found after the valve-in-valve procedure. It is potentially related
to the material and geometry constrain of the old bioprosthetic devices, especially
specific stented porcine surgical valve types133.
However, there is limited optical access to the neo-sinus region. 2D PIV measurement
cannot capture the 3D experimental result at the neo-sinus region. The other techniques,
like dye injection, can only measure the average value for blood washout from the neo90

sinus region. The FSI technique allows us to estimate the result in inaccessible regions. In
this study, one-way FSI was used to conduct the simulation. The downstream
experimental and simulation data were compared to validate the simulation result.
5.3

Method
In this study, a “generic” intra-annular TAV model with similar design features to the

Edwards SAPIEN 3 was developed to investigate the dynamic flow characteristics of the
neo-sinus.
5.3.1

Experimental Setup

The experiment was conducted using pulse duplicator testing and PIV. The boundary
conditions for the simulations were obtained from the pulse duplicator testing.
Subsequently, the simulation result was validated with the PIV testing result.
5.3.1.1

Pulse Duplicator Test

The experiment was set up in the pulse duplicator. 26-mm Medtronic CoreValve and
26-mm Edwards Lifesciences SAPIEN 3 devices were considered. The devices were put
in a customized washer to hold the valve device in the silicon heart while in the pulse
duplicator. The washers were printed with a U-Print SE Plus 3D printer (Stratasys Ltd.,
Eden Prairie, MN). The internal dimension of the washer was designed as 26 mm to fit
the valve devices. The printed washer is shown in Figure 5.1. One thin layer of Teflon
was wrapped around the washer to improve the sealant and fraction between the
bioprosthetic device and the washer.
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Figure 5.1 Washer used in pulse duplicator (Left: top view, right: side view)
The bioprosthetic valves were then placed in the in-vitro pulse duplicator system from
BDC Labs (Wheat Ridge, CO). The testing condition was set to normal physiological
condition based on the international standard ISO-5840 recommendations. Such as 70
beats/mins, mean aortic pressure of 100 mmHg, and the cardiac output was set to 5L/min.
The normal saline/glycerin solution was mixed at 45%/55% to mimic the blood in the
body under 37 Celsius. Phosphate-buffered normal saline solution (PBS 100 ml tablets,
Research Products International, Mount Prospect, IL) and glycerin solution (99%
glycerin, The Science Company, Denver, CO, USA) were used to prepare the solutions.
The particle imaging velocimetry testing was done in the previous studies by Barakat
et al.137. The result was utilized in this project to verify the simulation result.
5.3.2

Simulation

5.3.2.1

Geometry

During the experiment, the washer around the valve device creates a neo-sinus region
around the newly implanted valve device; therefore, the interior wall of the washer can be
considered as the leaflet of the old valve device. The geometry of the pulse duplication
was obtained from the BDC laboratory. Since the geometry of the cylindrical pip and the
geometry of the valve devices were axial symmetric, the simulation models can be
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simplified into one-third of the whole geometry. Figure 5.2 shows the geometries when
the valve devices are placed in the outflow region of the pulse duplicator. (a) and (d)
illustrated the geometries when the leaflet and stent were in the fluid volume. The stent
and skirts were removed from the geometry by considering the regions that contain both
skirt and stent as a 0.5 mm solid stationary geometry in (b) and (e). The geometries were
simplified as 1/3 of the geometry to reduce further the computational cost, shown as (c)
and (f).
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Figure 5.2 The concept geometry and geometries of the CFD model, (a)-(c) are the
iterations for generic 26-mm SAPIEN 3 model geometry, and (d)-(f) are the iterations of
the 26-mm CoreValve model geometry.
5.3.2.2

Simulation Setup

The meshes were imported to ABAQUS/Explicit solver for simulation in structural
analysis. The Fung anisotropic hyperelastic material model was applied to the leaflet. The
orientation of the material was generated using a MATLAB code so that one of the leaflet
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edges was aligned with the free edge, and the other two edges were aligned orthogonally
with the first direction. The normal direction of the material orientation was identical to
the normal direction of the corresponding shell element. The wall of the simplified stent
and two planes at the symmetric planes were used to control the movement of the leaflet.
Two cardiac cycles of transvalvular pressure gradient curves were applied uniformly on
the leaflet during the simulation. Meanwhile, the fixed edges of the leaflets were fixed in
six degrees of freedom. The details of the FE simulation were described in the previous
chapter. After the FE simulations, the nodal locations of the structural analysis were
extracted. A homemade MATLAB code was used to generate frames for the two cardiac
cycles with an interval of 0.1 ms.
In ANSYS fluent, simulation was set up using a k-ε standard model to simulate the
transient turbulent flow behavior of the flow. The bottom surface was set as the pressure
inlet, and the top surface was considered the pressure outlet. The external walls and the
leaflet were set as walls. The two planner surfaces were considered as the symmetric
plane. The pressure gradient for the structural analysis was applied uniformly on the
surface at the pressure inlet. The outlet was set as 0 Pa gauge. Two user-defined scalars
were defined in the simulation to determine the blood residence time on the leaflets. The
region of interest denoted was defined as a section 2 mm above and 2 mm below the
leaflet geometry.
An Eulerian approach was used to quantify the BRT value. The residence time
donates as TR in the following equation113.
𝜕𝜕𝑇𝑇𝑅𝑅
+ 𝒗𝒗 ∙ ∇TR = 1
𝜕𝜕𝜕𝜕
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𝒗𝒗 in the equation is the flow velocity vector. This equation was solved simultaneously
with continuity and the conservation of momentum equations. A scalar was used to

quantify the BRT value in the region. It started from 0 s at the flow inlet, which is the
bottom surface of the model. The TR increases when the particle enters the region of
interest. The particles not entering the region of interest will be counted as 0125,126.
5.3.2.3

Mesh Independency Study

The mesh independence of the structural analysis of the leaflets in both devices was
analyzed in the previous studies. This section was focused on the mesh independence of
the CFD model.
The simplified geometries have meshed in Pointwise. The fluid region was divided
into three sections to control the mesh density. The top and bottom regions were meshed
with a coarse mesh. The middle region was meshed with a finer since the simulation
result in the central region was the point of interest. The CoreValve and SAPIEN 3
models mesh become mesh independent when the number of tetrahedral elements is
larger than 209448 and 278783, respectively. The detailed mesh independent study is
shown in 8.3.2.
5.4

Result
5.4.1

Comparison between Supra-annular design and Intra-annular design

The velocity profile shows a good agreement between the experimental and
simulation results. The velocity contour at the peak of flow is shown in Figure 5.3.
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Figure 5.3 The middle plane 2-dimensional velocity magnitude comparison at the
peak of flow. (Note: the CoreValve was idealized, the geometry of the actual leaflets are
not identical.)
During the peak of flow, the maximum velocity is located at the center of the contour.
The jet of the SAPIEN 3 valve showed short and wide profiles in both PIV testing and
generic intra-annular design simulation results. In contrast, both results showed that the
CoreValve jet exhibited slimmer and longer profiles. The maximum velocity values at the
peak of flow in the simulation were 2.8 m/s and 3.1 m/s for SAPIEN 3 and CoreValve
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devices, respectively. The PIV result showed a similar value in the raw data. After
excluding the extreme pixels in the PIV result. The maximum values at the peak of flow
were 2.4 m/s for SAPIEN 3 and 2.6 m/s for CoreValve.
The blood was washed out from the neo-sinus region during systole when the valve is
opening. The BRT built up during diastole on both valve device leaflets. Figure 5.4
shows the BRT on both valve devices at different time points during the first cardiac
cycle from the top view.

Figure 5.4 The BRT of two devices at different time points in the first cardiac cycle
(top row: 26-mm Edwards Lifesciences SAPIEN 3 valve, bottom row: 26-mm Medtronic
CoreValve)
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Figure 5.5 Isotropic view of the 26-mm CoreValve and 26-mm SAPIEN 3 valve at
the end of the first diastole.
The maximum BRT value happens at the end of the diastole. According to Figure
5.5, the maximum value on the SAPIEN 3 valve device is located near the fixed edge. In
contrast, the maximum BRT value on the CoreValve device was located at the lower
belly region, matching the covered area. On the other hand, the upper portion of the
CoreValve had a lower value when compared with the upper area of SAPIEN 3. A higher
value was not observed on the fixed edge of the CoreValve device. Histograms of the
BRT on the leaflets at the end of the diastole were plotted in Figure 5.6 and Figure 5.7.
The residence time on the CoreValve device has a wide distribution range. It has the
highest percentage, 22.59%, between 0.9 s and 1 s. While the whole surface of SAPIEN 3
leaflets has a BRT value higher than 0.4 s. Nearly half of the area have BRT value
between 0.4s and 0.5s.
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Figure 5.6 The histogram of BRT on 26-mm CoreValve leaflets at the end of the first
cardiac cycle.
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Figure 5.7 The histogram of BRT on 26-mm SAPIEN 3 leaflets at the end of the first
cardiac cycle.
5.4.2

Flow Analysis of Intra-annular Design

The flow contour at different time points is shown in Figure 5.8. The results are
presented in mid-plane, 30 degrees from mid-plane, 55 degrees from mid-plane, and
horizontal cross-sections. The high-velocity jet was observed along the axial direction. At
the peak of flow, the maximum velocity magnitude width was observed as 2.6 m/s in the
middle of the jet while the jet width was 19.5 mm. the leaflet motion was the key factor
that drives the flow in the neo-sinus region. The velocity in the neo-sinus region
increased during early systole. When the leaflets reached the maximum opening, the
velocity magnitude had the lowest overall value, nearly 0 m/s. Subsequently, the velocity
increased while the leaflets were closing. It decreased after the valve reached full closure.
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Figure 5.8 Velocity magnitude contours, top row: the cross-section view 55 degrees
from the mid plane; second row: the cross-section view 30 degrees from the mid plane;
third row: the middle plane; bottom row, the horizontal cross-sections.
Massless imaginary particles were introduced to evaluate the flow in the neo-sinus
region and presented in Video 8.6. The massless particles, representing blood cell
components, are shown by black dots. The path of the particles illustrated the flow
behaviors such as flow path, vortices, and swirls in the neo-sinus region. As shown in the
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video, the majority of the particles were washed out during a normal cardiac cycle. The
particles near the free edge were able to be completely washed out. In contrast, a
considerable amount of particles stayed near the fixed edge of the valve device in the
neo-sinus region.
The BRT contours presented in Figure 5.9 were the BRT values on the leaflets at
multiple time points during a cardiac cycle. The top row represents the BRT on the
surface of the leaflet. High BRT regions were concentrated near the fixed edge of the
leaflet and are shown as red in the contour. The second, third, and fourth rows were the
contours of the cross-section result of the fluid domain on three vertical planes, 0 degrees,
30 degrees, and 55 degrees from the midplane. According to the results, BRT
distributions were highly linked with the movement of leaflets during a cardiac cycle.
The limited motion of the leaflet at the fixed edge promotes the stasis of the particles on
the leaflets. Additionally, the BRT varies in time. When the valve reached a full closure,
distinct vortices were observed in the middle of the neo-sinus region. While the BRT in
the fluid domain near the fixed edge accumulated over time. The BRT value in that
region was almost identical to the simulation time. The maximum BRT value is 0.966 s at
0.991 s.
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Figure 5.9 BRT during a cardiac cycle. Top: the BRT on the leaflet; second: the
cross-section view at the plane 55 degrees from the midplane; third: the plane 30 degrees
from the midplane; bottom: the result on the midplane.
As one of the thrombosis formation factors, the wall shear stress on the leaflet was
investigated. Figure 5.10 shows the wall shear stress on the aortic and ventricular sides of
the leaflet. The result indicates that the shear stresses on the ventricular side of the leaflet
were generally higher than on the aortic side. The maximum shear stress was lower than
100 Pa.
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Figure 5.10 Wall shear stress on the leaflet, top: aortic side; bottom: ventricular side.
5.5

Discussion
This study analyzed the BRT supra-annular self-expandable CoreValve and the intra-

annular balloon-expandable SAPIEN 3 to determine the risk factor of thrombosis in the
two types of devices. The high BRT value regions indicate a high thrombosis risk in the
lower belly region on the CoreValve device and near the fixed edge of the SAPIEN 3
device. The analysis of the SAPIEN 3 BRT indicates that the local variation, such as the
local leaflet motion, flow path, and time is highly associated with the BRT. Therefore, the
average BRT value in the neo-sinus region may not fully describe the risk of blood stasis
on the leaflet surface.
Subclinical leaflet thrombosis is a potential risk in patients who received TAVR.
Thrombosis was found under 4-dimensional computed tomography on supra-annular
design and intra-annular design 19,124. The increased thrombosis is hypothesized to be the
leading cause of early valve failure 138. The increased blood stasis could promote the
formation of thrombosis139. In the generic SAPIEN 3 model, although the high shear
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stress is located at the ventricular side free edge, the shear stress magnitude and the
duration are lower than the threshold. Thus, the shear stress is not the predominant risk
factor for thrombosis formation for the generic SAPIEN 3 model.
The overexpanded SAPIEN 3 and CoreValve/Evolut R with high implantation depth
were found to have higher thrombosis risk from clinical data. It is hypothesized that the
risk is associated with the stasis volume 19. Since the maximum velocity happens during
systole, the enclosed volume is the stagnation zone. The overexpanded SAPIEN 3 and
deeply implanted CoreValve are likely to have enlarged stagnation zones. The SAPIEN 3
valve is designed to be implanted at an intra-annular position. Therefore, the implantation
depth change does not alter the enclosed volume. However, the CoreValve device
implantation depth is directly associated with the stagnation volume. The high BRT zone
has a high coincident with the covered region on the lower belly region. Additionally, the
limited motion at the CoreValve lower belly region enlarged the volume. As a result,
CoreValve leaflets had more area exhibiting high BRT than the SAPIEN 3 leaflets at the
end of diastole when the valve bottom is implanted at the exact location.
The constrain around the valve device is comparable with the valve in valve
configuration. Thus, the same trend applies to patients who receive the ViV procedure. In
order to use the TAVR procedure in the low-risk patient, the high BRT needs to be
addressed. The physicians may want to find an optimal implantation depth for the supraannular design. The future valve design may focus on reducing the stasis volume in the
neo-sinus region, such as reducing the immovable leaflet region in the leaflet design and
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modifying the design to be implanted in a supravalvular location without causing
complications.
5.5.1

Limitation

The first limitation is that the patient-specific geometry is more complex than the
pulse duplicator. The calcification, the wall geometry, and the coronary flows could alter
the flow field. However, the result from this study is still insightful for us to understand
the potential risk of thrombosis. The single cardiac cycle also limits this study. The result
could provide us with the location of the high BRT value but not enough to determine the
blood washout time. Future studies are proposed to include more cardiac cycles to
analyze the SAPIEN 3 device washout time. It might be possible that the blood can be
washed out of the stagnation zone in the following cardiac cycles, as observed in
experiment 19. Finally, the PIV testing used a different washer in the system. The washer
used in the PIV testing does not have the upper ridges. It is one of the potential reasons
why the maximum flow velocity observed in the PIV testing is about 12% lower than the
simulation result.
5.6

Conclusion
Although leaflet thrombosis formation is associated with multiple factors, this study

provided insights into the BRT distribution following TAVR. The high BRT value is
located within the neo-sinus region. The blood is likely to be trapped in the stasis region.
In addition to the confined region, leaflet connection on the generic SAPIEN 3 device
and kinematics of the CoreValve device is linked to the promoted stasis. Future clinical
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investigation and in vitro studies are needed to have a more comprehensive understanding
of the findings in this study.
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Chapter Six: Hemodynamic Analysis of Transcatheter Aortic Valve Devices after
Valve-in-Valve Procedure by BASILICA
6.1

Overview
The previous study used the pulse duplicator model to evaluate the BRT on the

leaflets. The BRT is potentially low in the patient due to the complex geometry and the
flow induced by the coronary arteries. In recent years, bioprosthetic aortic scallop
intentional laceration to prevent Iatrogenic coronary artery obstruction, also known as
BASILICA procedure, was developed to prevent the potential coronary artery blockage.
We hypothesize that this procedure could reduce the BRT since it creates an opening on
the old leaflet. The goal of this study was to investigate the impact of BASILICA on the
BRT following TAVR. In this study, my main contributions are the geometry
construction and finite element analysis sections.
6.2

Background
Subclinical leaflet thrombosis is more frequently observed on the TAV device

following TAVR and ViV procedure than on SAV 77. The occurrence of leaflet
thrombosis is reported to be from 4.5% to 40% 77,111,140-143. Patients with leaflet
thrombosis have a higher risk of stroke 111. The early thrombosis can be resolved by
anticoagulation therapy 77. However, it is associated with an increased risk of
complications such as bleeding 144. Therefore, an alternative way needs to be found to
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minimize thrombogenicity following TAVR without or with minimal complications to
prolong the durability of the valve device.
In the previous study, the computational simulation was conducted to evaluate the
thrombosis formation risk by analyzing the blood stasis time on the bioprosthesis leaflets
112,113

. Other than the SAVR, which removed the native valve and diseased, the TAV

procedure is either placed in the calcified native leaflet in normal TAVR or in the
malfunctioned bioprosthesis in the ViV procedure. The old leaflet along with the stent
frames created a confined region around the new leaflet. The region between the
confinement wall and the new leaflets is usually called the neo-sinus region. The
confinement pushes the old leaflets towards the coronary and can potentially block the
coronary arteries. The blocked coronary could lead to severe complications and increase
the mortality risk 145.
Furthermore, the BRT is also found to be increased on the TAV leaflets112,113. The
increased BRT increases the chance for the activated platelets to interact with the proteins
and accumulate, which will lead to increased thrombosis risk 131. The previous study
found that the supra-annular leaflet positioning could reduce BRT113. The previous
chapter also indicated that the high BRT is within the confined region.
BASILICA procedure is a valve modification procedure that lacerates the
degenerated bioprosthetic valve leaflets to open the neo-sinus region. It is hypothesized
that the blood washout could be improved with an opened neo-sinus region. This study
aims to determine the leaflet thrombosis formation risk following BASILICA. This study
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analyzed the hemodynamics near the valve device in a patient-specific geometry using a
one-way FSI simulation of an intra-annular TAV device.
6.3

Method
Patient-specific normal aortic root geometry was extracted from computed

tomographic angiography (CTA) images and reconstructed using ScanIP image
processing software (Simpleware Ltd., Exeter, UK). Subsequently, the 26-mm SAPIEN 3
valve was mounted in a 29-mm Mitroflow, a surgical valve device, with a labeled
geometry. Two scenarios were considered in this study to evaluate the impact of the
BASILICA procedure, the 26-mm SAPIEN3 valve in an intact 29-mm Mitroflow valve
and the 26-mm SAPIEN3 valve in a lacerated 29-mm Mitroflow valve. Same with the
previous one-way FSI simulations, only leaflet and fluid domains were modeled.
According to previous studies, the stent was considered rigid and removed from the
whole domain according to the previous study112,113,146. In the BASILICA model, the
lacerations were created on all three leaflets of the surgical valve, comparable with the
clinical data.
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Figure 6.1 Models in SolidWorks (left: the geometry with intact surgical valve. right:
the geometry following BASILICA)
The detail of the one-way FSI simulation procedure was described in previous
chapters. Initially, FE simulations were conducted based on the boundary conditions
obtained in the pulse duplicator using normal physiological conditions. The fixed edges
were fixed at six degrees of freedom, and the transvalvular pressure curve was applied to
the leaflet surface. The nodal location of the leaflets was exported from the FE simulation
result and subsequently applied in a homemade MATLAB function to generate the
frames. Then the CFD simulations were performed while updating the leaflet location
based on the frames.
During the CFD simulation, the k-ε model was used to simulate the transient
turbulent flow model. The fluid material was defined as 1060 kg/m3 and 0.0035 kg/(m⋅s).
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An Eulerian approach was used to quantify the BRT value. The residence time TR can be
represented using the following equation113.
𝜕𝜕𝑇𝑇𝑅𝑅
+ 𝒗𝒗 ∙ ∇TR = 1
𝜕𝜕𝜕𝜕

where 𝒗𝒗 is the flow velocity vector. This equation was solved simultaneously with

continuity and the conservation of momentum equations. A scalar was used to quantify
the BRT value in the region of interest. The region of interest is defined as the fluid
domain between 4.5 mm below and 2.5 mm above the valve device. Details can be found
in the previous chapters.
6.4

Result
The flow velocity magnitude is presented in Figure 6.2. The top row represents the

model with no laceration on the old leaflet. In comparison, the bottom row is the model
with the BASILICA procedure. The contour shown in the figure was the flow velocity
magnitude at the middle plane. Massless particles were introduced to represent the
movement of the blood within the flow domain. The overall flow profile was similar. The
major difference observed between the two models in the flow domain was located in the
sinus region. During systole, a significant number of particles were observed flowing
toward the coronary arteries in the model with the BASILICA procedure.
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Figure 6.2 The velocity magnitude contour at the middle plane at different time points
(black dots represent the massless particles)
During systole, the BRT contour is similar between the two models. In contrast, the
BRT in the leaflets with the routine ViV method was higher than that in the BASILICA
model during diastole. The BRT at five different time points is shown in Figure 6.3. The
high BRT values were concentrated on the leaflets near the fixed edges. The average
BRT values were calculated to quantify the BRT on the leaflets in the two different
models. At the end of diastole, the BRT value following BASILICA was 9.8% lower than
that without BASILICA. The BRT value is also highly dependent on the location. The
non-coronary artery had a 22.8% higher BRT value when compared with the leftcoronary artery at the end of diastole. However, the right coronary artery had a similar
BRT value to the left coronary artery at the same timepoint. The BRT on the right
coronary artery leaflet was only about 2.7% higher than on the left.
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Figure 6.3 Blood stasis time on the leaflet at five different time points in one cardiac
cycle (a: the ViV model without BASILICA; b: the ViV model with BASILICA)
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Figure 6.4 The percentage area with BRT larger than 0.5 s at the end of diastole.
Some researchers indicated that the platelet activation time is between 0.1 to 0.5 s147149

. 63.2% of the TAV leaflet surface have BRT larger than 0.5 s in the model without the

BASILICA procedure. This value was reduced to 47.7% following BASILICA. The BRT
value was highly reduced on the coronary leaflets. According to Figure 6.4, the area with
BRT larger than 0.5 s was reduced from 50.5% to 37.3% on the left coronary artery
(LCA) following BASILICA. In contrast, this area on the right coronary artery (RCL)
decreased from 72.2% to 67.9%.
6.5

Discussion
Valvular diseases are public-health problems since the risk increases with age, and

aging has become a global issue150. The surgical valve has been used in 90% of patients
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in the surgical approach to reduce the use of lifelong anticoagulation treatment151. The
durability of bioprosthesis is considerably shorter than the mechanical valve
implantation. The patient may need to receive a second valve implanted when the patient
has a malfunctioned bioprosthetic valve, either SAV or TAV. The ViV procedure is an
ideal option for patients with a low survival rate following an open-heart surgery to
replace the diseased bioprosthesis. However, the durability of the TAV device is still one
of the major concerns before it is widely used. Joes et al.76 reported that the leaflet
thrombosis risk is higher in patients who underwent the ViV procedure than those who
received TAVR. Del Trigo et al.141 found that the ViV procedure is an independent
predictor that can increase TAV hemodynamic deterioration.
It was postulated that the covered region created a pocket and led to local blood
stagnation135. Following the BASILICA procedure, the laceration on the diseased leaflet
could open the pocket and allows blood to exit. The movement of massless particles
indicated that the blood is washed out of the neo-sinus region. This efficiency reduces the
blood stasis on the leaflets, especially on the left and right coronary leaflets. Therefore,
the selected lacerations on the left and right degenerated coronary leaflets could be
sufficient to reduce the risk of leaflet thrombosis. Further studies are motivated to assess
the best strategery to create the lacerations on the degenerated leaflets.
One of the limitations is associated the geometry. The patient-specific geometry is
obtained from a healthy person. However, the valve lesions are usually associated with
altered local aortic root and aorta geometry. Therefore, multi-scale and multi-physics
models are needed to comprehensively understand the effect of the BASILICA on the
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ViV procedure. Moreover, further in-vivo or in-vitro experiments and clinical data could
help validate the result.
6.6

Conclusion
The current study indicates that the BASILICA procedure could promote blood

washout following ViV implantation. Therefore, BASILICA is a potential solution to
reduce the leaflet thrombosis risk. Physicians may want to evaluate the risk and suggest
the BASILICA procedure to the selected patient to reduce the postprocedural leaflet
thrombosis risk.
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Chapter Seven: Conclusion and Future Works
TAVR is a well-established approach to treating high-risk and intermediate-risk
patients with severe aortic stenosis. Moreover, recently it has been accepted to use in
low-risk patients. Given the promising outcome of the TAVR, it could potentially
become a promising approach for low-risk patients. However, the low-risk patients
usually have a younger age. Therefore, they have a higher life expectancy than the highrisk and intermediate-risk patients. They have a high demand for more extended TAV
device durability. To widely apply the TAVR procedure to low-risk patients, the TAV
device needs to have comparable durability to the SAV devices. However, the local
geometry of the valve devices is complex. Since the TAVR procedure does not remove
the malfunctioned valve and calcification at the aortic position, the local environment can
highly impact the deployed TAV shape. Concerns are raised regarding the impact of the
local geometry on the newly implanted valve device. However, there is limited clinical
data on the long-term durability of the valve devices, not to mention the investigation of
specific geometry constrain types. Computation simulation using finite element analysis
and computational fluid dynamics could provide insight into the impact of a particular
condition. This dissertation aimed to conduct structural and hemodynamic analyses to
evaluate the long-term durability of TAV devices. The main conclusions of the studies
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included in this dissertation are summarized in this chapter. The proposed future works
are related to the presented studies.
7.1

TAV in Bicuspid Aortic Valve
Bicuspid aortic valve patients are likely to experience severe aortic stenosis at their

younger age, which is expected to be categorized as low-risk patients. They are likely to
receive the second or third valve replacement in their lifespan. Thus, it is critical to
ensure the valve devices have good long-term durability. However, the valve devices are
commonly deployed in elliptical shape in the patients. We analyzed the stress and strain
on the leaflets. The result indicates kinematic is impaired when the valve device is
elliptically deployed. The high stress and strain in the region close to the compressed
leaflet fixed edge could lead to a high chance of material tear and fatigue, which will lead
to reduced valve durability. Post-procedural balloon dilation could be an option to reduce
the ellipticity and prolong the TAV device’s long-term durability.
7.2

Regionally Under Expanded TAV
The complex local geometry of the stenotic valve may lead to the uneven deployment

of the TAV device. The calcifications can block the expansion of the valve device and
lead to regional under expansion. The regional under expanded device usually results in
impaired leaflet motion on the small-angle leaflet. It has a reduced maximum opening
and leads to a delayed closing. This change could lead to higher blood stasis time on the
leaflet and increase thrombosis risk.
Additionally, the stress on the leaflet near the bottom of the fixed edges increases as
the small-angle decreases. Therefore, the material deterioration could happen on the
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leaflet near the connection between the biological material and the stent. To ensure longterm durability, physicians may want to find a way to reduce the regional underexpansion of the valve device following the TAVR.
7.3

Hemodynamic Analysis of the Self-expanded Valve
The degenerated leaflet and the newly implanted TAV device can form a volume that

prevents the blood from being washed out. The blood stasis can lead to increased
thrombosis risk. The washer in the pulse duplicator created a similar environment to this
scenario. The simplified geometry can help us have a general idea about hemodynamics.
The simulation result indicates that most of the supra-annular design neo-sinus region
blood could be washed out within one cardiac cycle. However, the blood could
accumulate in the region near the fixed edge due to the limited leaflet motion. The future
TAV design may want to improve the leaflet motion at the lower belly region to promote
the blood washout in that region.
7.4
Hemodynamic Analysis Comparison between the Intra-annular Design and
Supra-annular Design
The blood stasis on the intra-annular in the pulse duplicator was compared with the
supra-annular design. Other than the supra-annular design, the intra-annular design sits
inside the degenerated valve. We observed that high BRT is concentrated on the fixed
edge and primarily located at the commissures of the newly implanted valve. The threedimensional flow during the cardiac cycle can assist the blood washout at the belly region
of the valve device. However, the flow change is not sufficient near the fixed edges. The
future intra-annular design is motivated to improve the fixture design to reduce the area
with limited motion.
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7.5

BASILICA’s impact on balloon-expandable valve
BASILICA is firstly introduced to resolve the coronary artery blockage following the

implantation of the TAV. The lacerations introduced on the degenerated leaflets also
provided an exit for the blood in the neo-sinus region. The presented hemodynamic study
of the BASILICA procedure following ViV with an intra-annular TAV proved the
hypothesis. The result indicated that the lacerations and the coronary artery flow
promoted the blood washout at the neo-sinus region. It also reduced the BRT value on the
leaflets. It is postulated that the BASILICA procedure could considerably reduce postprocedural leaflet thrombosis. Physicians may want to apply BASILICA to low-risk
patients to improve the sub-clinical outcomes.
7.6

Future works
The presented studies are limited due to a few factors. In order to have a better

understanding of the problems, those limitations need to be addressed. Firstly, the valve
device geometries are created based on the 3D scanned data of one 26-mm CoreValve
device and one 26-mm SAPIEN 3 device. The individual differences between the devices
could not be eliminated. The future study may want to take the dimension measurements
from group-average values to reduce the error caused by this. Secondly, the conditions
specified in the studies were idealized based on the clinical data. The in-vivo
environments in the patients are usually more complex than the specified dimensions.
Therefore, future studies may want to apply patient-specific dimensions to understand the
structural and hemodynamic change of the device in a particular patient. In addition,
there is limited experimental data to validate the simulation comprehensively. The future
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study wants to include precise dimension references and markers to quantify the area and
the displacement from the image data. Finally, the TAV devices' labeled geometry was
considered the stress-free condition during structural analysis. Future studies are
motivated to consider the TAV process to understand the impact of crimping and
deployment procedures.
This dissertation evaluated hemodynamics within the neo-sinus region in FSI
simulation, which provided more details for the findings from experiments. The future
study can implement simulations to evaluate the results which can not be obtained in the
experiment due to the limited optical access. An optimization procedure can be
considered to find the ideal design changes for the valve devices by reducing the stress
and blood stasis on the design to prolong the valve devices' long-term durability.
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Chapter Eight: Supplementary Material
8.1

Videos
8.1.1

Structural Analysis of the Transcatheter Aortic Valve Devices in

Bicuspid Aortic Valve Patients

Video 8.1 Comparison of experimental and simulation results when the CoreValve
device is highly elliptically expanded.
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8.1.2

Structural Analysis of the Self-Expandable Bioprosthesis with Regional

Under-Expanded Geometry

Video 8.2 Comparison between the pulse duplicator testing and the experiment
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8.1.3

Hemodynamic Analysis of the Supra-annular Biophrosthesis

Video 8.3 Comparison of the experimental record and the simulation result of fully
expanded 26-mm CoreValve leaflet motion from the top view.

Video 8.4 Video of the 26 mm-CoreValve motion in two cardiac cycles.
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Video 8.5 The velocity contour in the second cardiac cycle with particles.
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8.1.4

Hemodynamic Analysis of the Intra-annular Biophrosthesis

Video 8.6 Particle movement in the neo-sinus region
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8.2

Material Properties
Table 8.1 The material properties of the stent for the nitinol alloy CoreValve stent and
the cobalt-chromium SAPIEN 3 stent108,109.

Valve Type

CoreValve

Material

Nitinol alloy

CobaltSAPIEN 3

chromium
alloy (MP35N)

Properties
Austenite elastic modulus (MPa)

51700

Martensite elastic modulus (MPa)

47800

Poisson's ratio

0.3

Start of transformation loading (MPa)

600

End of transformation loading (MPa)

670

Start of transform unloading (MPa)

288

End of transformation unloading (MPa)

254

Reference temperature (K)

310

Maximum transformation strain

0.063

Maximum volumetric transformation strain

0.063

Density (kg/m3)

6500

Young modulus (MPa)

232800

Poisson’s ratio

0.3

Yield stress (MPa)

414

Density (kg/m3)

8000

The 3-dimensional strain maps of the biological materials in the valve devices were
obtained using digital imaging correlation (DIC)146. Those data were used to obtain the
optimal material properties in Fung anisotropic hyperelastic model106. The following
145

equation is the generalized form of Fung’s anisotropic hyperelastic model strain energy
function.
𝑐𝑐

2
−1
1 𝐽𝐽𝑒𝑒𝑒𝑒

𝛹𝛹 = (𝑒𝑒 𝑄𝑄 − 1) + (
2
Ɗ

2

− ln 𝐽𝐽𝑒𝑒𝑒𝑒 ),

where 𝛹𝛹 is the strain energy per unit reference volume, Ɗ and c are temperature-

dependent properties, 𝐽𝐽𝑒𝑒𝑒𝑒 represents the elastic volume ratio, and 𝑄𝑄 = 𝐸𝐸: ( 𝕓𝕓𝐸𝐸) . Where 𝕓𝕓
is a symmetrical non-dimensional fourth-order tensor. The values in the cells correspond
to the material properties input values in ABAQUS.

The CoreValve leaflet and skirt component material properties have the c=100.29 kPa
and α=8313 1/s. The CoreValve leaflets material properties 𝕓𝕓 can be represented by the
following parameters

𝕓𝕓𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶

⎡
⎢
⎢
⎢
⎢
=⎢
⎢
⎢
⎢
⎢
⎣

64.10

38.51

63.25

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆

57.14

18.89

44.91

71.65

42.18

69.83

45.96

62.37
15.45

61.13
14.33
43.87

47.58

⎤
⎥
25.19
⎥
⎥
58.04 ⎥
⎥
27.93 ⎥
⎥
17.01 ⎥
⎥
66.12 ⎦

The SAPIEN 3 leaflets' material properties have c= 47.53 kPa and the viscous
damping α=4800 1/s. The tensor 𝕓𝕓 can be written as
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𝕓𝕓𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 3

8.3

⎡
⎢
⎢
⎢
⎢
=⎢
⎢
⎢
⎢
⎢
⎣

87.45

37.88

83.97

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆

56.25

18.49

45.47

89.93

43.70

62.41

43.50

70.21

13.92

71.65

15.12
43.54

37.23

⎤
⎥
25.72
⎥
⎥
58.98 ⎥
⎥
27.96 ⎥
⎥
16.47 ⎥
⎥
68.56 ⎦

Mesh Independence Study
8.3.1

FE simulations

A mesh independence study was conducted with several different mesh densities for
both types of valve devices. The mesh of the leaflet-skirt component was analyzed for the
CoreValve device since the leaflet and skirt were made from one piece of porcine
pericardium. At the same time, the leaflet component of the SAPIEN 3 device was
evaluated. The geometries meshed with S4 elements in HyperMesh. During the meshing
procedure, the elements were created by aligning the orthogonal edges with the two
different fiber directions. The finalized meshes were then transferred to
ABAQUS/Explicit solver.
Fung anisotropic hyperelastic material properties were assigned for the corresponding
models to represent the porcine pericardium in the CoreValve device and the bovine
pericardium in the SAPIEN 3 valve device. The orientation of the elements was
individually created in MATLAB so that one fiber direction was assigned along two
parallel element edges, and the other fiber groups were defined along the element edges
that are orthogonal with the other fiber group.

147

A uniform pressure was applied to the leaflets from 0 mmHg to 40 mmHg in 0.1 s.
Meanwhile, the CoreValve device’s skirt and the SAPIEN 3 device’ fixed edges were
fixed at six degrees of freedom during the simulations. The max in-plane principal stress
at the end of the simulation was compared to compare the accuracy of the three
simulations result.
The comparisons are shown in Table 8.2. In the CoreValve model, the large
difference observed between Medium and Fine mesh was probably caused by the
orientation difference. Therefore, the Finer mesh was created to validate the result of the
Fine mesh. The Fine mesh has a 1% difference compared with the max in-plane stress
result from the mesh with a doubled number of elements. Thus, the Fine mesh, which has
641626 S4 elements, was used to conduct the simulation. The SAPIEN 3 model max inplane principal stress value indicates that the result becomes mesh independent when the
number of elements becomes more than 3210.

Table 8.2 Table of mesh independence study for FE simulation
26-mm CoreValve
Mesh Density

Coarse

Medium

Fine

Finer

Number of element

3912

7239

14687

37104

Max in-plane stress (Pa)

613976

515812

641426

650367

6%

21%

1%

0%

Percentage error
(compared with the result
from Finer mesh)
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26-mm SAPIEN 3
Mesh Density

Coarse

Medium

Fine

Number of element

1500

3210

6000

Max in-plane stress

1382440

1463290

1447300

4%

1%

Percentage error
(compared with the result
from Fine mesh)

8.3.2

CFD Simulations

A mesh independence study was conducted using the simplified geometries for the
CFD simulation. The testing was conducted while the valve devices were closed. The
geometries were created in SolidWorks and imported to Pointwise (Pointwise, Fort
Worth, Texas) for meshing. The exterior cylinder wall and leaflet were assigned as walls.
The bottom and flat top surfaces were defined as pressure inlet and outlet. Surfaces on the
symmetric plane were defined as symmetry. The 3D elements domain was defined as
fluid.
Subsequently, the generated models, coarse, medium, and fine, were imported to
ANSYS fluent for CFD simulation. K-epsilon model was used during the simulation to
simulate the transient turbulent flow behavior. The material was defined as the blood,
1060 kg/m3, and 0.0035 Pa*s, representing the glycerin/normal saline solution mixture in
the pulse duplicator system. In the boundary condition, a pressure ramp increased from 0
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mmHg to 40 mmHg in 0.1 s was applied at the pressure inlet. The pressure outlet was
assigned with 0 gauge pressure since the outlet was directly connected to the atmosphere.
The result was calculated with a time step of 0.001 s and 500 iterations for each time step
with residual criteria set as 10e-10. Finally, the velocity magnitudes from the simulation
with different mesh densities were compared and shown in Table 8.3.
Table 8.3 Table of mesh independence study for CFD simulation
26-mm CoreValve
Mesh Density

Coarse

Medium

Fine

Number of tetrahedral element

209448

445739

852016

Max velocity magnitude (m/s)

3.15

3.09

3.13

1%

1%

Mesh Density

Coarse

Medium

Fine

Number of tetrahedral element

278783

397915

702499

Max velocity magnitude (m/s)

3.549

3.547

3.548

0.03%

0.03%

Percentage error
(compared with the result from Fine mesh)
26-mm SAPIEN 3

Percentage error
(compared with the result from Fine mesh)

The percentage errors were calculated by (velocity magnitude from current meshvelocity magnitude from the fine mesh)/ velocity magnitude from the fine mesh. The
velocity magnitude percentage errors of the CoreValve CFD models were 1% for coarse
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mesh density and 1% for medium-mesh density. It indicates that the CFD model for the
CoreValve device will become mesh independent when the number of tetrahedral
elements is more than 209448. In contrast, coarse and medium mesh densities in SAPIEN
3 valve CFD models have a 0.03% difference compared with the fine mesh density result.
Thus, the SAPIEN 3 valve CFD model is mesh-independent when the number of
tetrahedral elements is more than 278783.
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